Self-assembled nanoparticles as new smart contrast agents for magnetic resonance imaging by Simão, Teresa
  
 
 
UNIVERSIDADE DO ALGARVE 
Faculdade de Ciências e Tecnologia 
 
 
 
SELF-ASSEMBLED NANOPARTICLES AS NEW SMART 
CONTRAST AGENTS FOR MAGNETIC RESONANCE 
IMAGING 
 
 
 
Teresa Fragoso Rocheta Simão 
 
 
 
 
 
Master’s Degree in Biomedical Sciences 
 
 
Faro, Portugal 
2010 
  
 
 
UNIVERSIDADE DO ALGARVE 
Faculdade de Ciências e Tecnologia 
 
 
 
SELF-ASSEMBLED NANOPARTICLES AS NEW SMART 
CONTRAST AGENTS FOR MAGNETIC RESONANCE 
IMAGING 
 
 
Teresa Fragoso Rocheta Simão 
 
 
Master’s Degree in Biomedical Sciences 
 
 
Project and thesis supervised by: 
Fouzi Mouffouk, Ph.D (CBME, IBB) 
Nuno Rodrigues dos Santos, Ph.D (CBME, IBB) 
 
Faro, Portugal 
2010
Self-assembled nanoparticles as new smart contrast agents for magnetic resonance imaging  2010 
T. Simão  i 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
“The secret of getting ahead is getting started. The secret of getting started is breaking 
your complex, overwhelming tasks into small manageable tasks, and then starting on 
the first one.” 
Mark Twain 
Self-assembled nanoparticles as new smart contrast agents for magnetic resonance imaging  2010 
T. Simão  ii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dissertação de Candidatura ao Grau de Mestre em Ciências Biomédicas  
Área de Bionanotecnologia pela Universidade do Algarve 
 
MSc Thesis in Biomedical Scienses  
Area of Bionanotechnology by the Universidade do Algarve 
Self-assembled nanoparticles as new smart contrast agents for magnetic resonance imaging  2010 
T. Simão  iii 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As opiniões expressas nesta publicação são da exclusive responsabilidade do seu autor 
 
The contents of this dissertation are of the exclusive responsibility of the author 
 
(Teresa Fragoso Rocheta Simão)
Self-assembled nanoparticles as new smart contrast agents for magnetic resonance imaging  2010 
T. Simão  iv 
ACKNOWLEDGEMENTS  
 
The work described in this thesis would have been almost impossible without the 
support and help of many people. 
 
 First, I would like to express my gratitude to my supervisors, Dr. Fouzi Moffouk 
and Dr. Nuno Rodrigues dos Santos. Thanks to Dr. Fouzi Mouffouk for the opportunity 
to work in this great project, for teaching me and trust in my capabilities to perform this 
task. Thanks to Dr. Nuno Rodrigues dos Santos for receiving me in his laboratory, for 
being such a dedicated professor, with who I learned so much, thanks to patiently listen 
to my ideas and doubts, to advice, assist and support me all over this work.  
A special thank you to Dr. Ana Costa, for being present whenever I needed, for 
gently teaching and conducting me during this work. 
Thanks to Dr. Ana Grenha, Dr. Gabriela Silva and Dr. Álvaro Tavares for being 
always there and to supply me so many precious informations.  
To my lab colleagues, Mónica Fernandes, Marinella Ghezzo and Ricardo Silva, 
thanks so much for sharing their knowledge, for their friendship, company and for 
always supporting me. Thanks to everyone at Dr. Guilherme Ferreira’s, Dr. José Belo’s 
and Dr. Ana Grenha’s laboratories for their suggestions and for helping me every time I 
needed. 
Thanks to my work colleagues for several schedule shifts, support and friendship. 
To all my friends, special tanks for their encouragement to continue and also for 
their companionship. I salute them for understanding and forgiving my lack of time to 
be with them.  
Lastly, I am very grateful to my parents and sister for being always a constant and 
unconditional source of support, affection, patience and understanding. 
 
Thank you very much to everyone! 
 
Teresa Simão 
 
 
Self-assembled nanoparticles as new smart contrast agents for magnetic resonance imaging  2010 
T. Simão  v 
ABSTRACT 
 
The aim of this thesis is to develop smart and targeted nanoparticle contrast agents for 
Magnetic Resonance Imaging. These nanoparticles were designed to improve the 
sensitivity of this high resolution imaging technique and thereby improve early cancer 
detection, which is a major factor for the reduction of cancer mortality. The designed 
nanoparticles are expected to accumulate in the tumor through passive and active 
targeting. In addition, when exposed to the characteristic low pH of the cancer 
microenvironment, the nanoparticles will release the contrast agent, which will turn on 
its imaging capability. This contrast agent consists of pH-sensitive polymeric micelles 
formed by self-assembly, loaded with Gadolinium (III) complexes and bioconjugated 
with the C595 monoclonal antibody against the human MUC1 protein, which is 
overexpressed during tumorigenesis since its early stages.  
The capability of micelles to disintegrate and release the encapsulated contrast in 
acidic conditions was proved by 1.5T MRI experiments. The MRI study showed no 
image signal from the sample with intact micelles whereas a signal enhancement was 
observed from the sample at low pH. After one mouse has been intramuscularly injected 
with Gadolinium(III)-loaded micelles in both hind legs, the MR image demonstrated a 
stronger signal from the right hind leg, which was previously injected with an acid 
solution. To assess in vitro cytotoxicity of free and encapsulated Gadolinium (III) 
complexes in polymeric micelles, MTT assays were performed on different cancer cell 
lines. Encapsulated Gadolinium (III) complexes showed significantly lower cytotoxicity 
than free Gadolinium (III) complexes, even at the highest concentration. To verify the 
target capability of nanoparticles, fluorescent dye-loaded polymeric micelles were 
incubated with breast cancer cells expressing MUC1 (verified by semi-quantitative RT-
PCR, Western blotting and flow cytometry) and mouse bone marrow stroma cells. 
Antibody-conjugated micelles had superior affinity for MUC1-expressing human breast 
cancer cells than for mouse bone marrow cells. 
 
Key words 
Smart contrast agent; Magnetic Resonance Imaging; Nanoparticles; Amphiphilic 
diblock copolymers; Mucin-1 
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RESUMO 
 
A presente Tese de Mestrado aborda a criação e síntese de um agente de contraste 
―inteligente‖ para imagiologia por Ressonância Magnética.  
A Ressonância Magnética (RM) é uma técnica de imagem médica que apresenta 
excelente resolução espacial e contraste entre tecidos diferentes. No entanto, por vezes a 
resolução de contraste não é suficiente para demonstrar alterações patológicas no 
mesmo tecido, especialmente quando as alterações ainda só estão presentes a nível 
celular e molecular. Para aumentar a sensibilidade desta técnica de imagem e potenciar 
a sua aplicação ao nível da imagem molecular desenvolveram-se nanopartículas com 
agente de contraste, específicas para detectar cancro. 
Este agente de contraste ―inteligente‖ é constituído por polímeros anfifílicos, 
sensíveis ao pH, que por self-assembly se organizam formando micelas. Estas, devido à 
característica particular do polímero que as forma, irão responder, desintegrando-se e 
libertando o seu conteúdo que consiste em quelatos de gadolínio (III) hidrofóbicos, 
exclusivamente perante ambientes com valores de pH relativamente ácidos, 
permanecendo intactas noutros meios. Enquanto o meio de contraste estiver 
encapsulado no centro hidrofóbico das micelas, elas restringem o acesso das moléculas 
de água ao quelato de gadolínio, o que impede a interacção dos protões da água com o 
ião metálico. Assim, não há diminuição do tempo de relaxação longitudinal (T1) das 
moléculas de água circundantes. Pretende-se, por isso, utilizar o pH extracelular 
relativamente ácido dos tecidos tumorais como despoletador específico da desintegração 
destas micelas e assim permitir que os quelatos de gadolínio aumentem o contraste da 
imagem de RM unicamente nestas situações. Esta diminuição localizada e específica do 
pH verifica-se desde as fases mais precoces do desenvolvimento tumoral, 
principalmente devido ao aumento da taxa de glicólise aeróbica das células 
cancerígenas. 
As micelas foram bioconjugadas com um anticorpo monoclonal, C595, contra a 
proteína Mucina-1 (MUC1) humana. Esta proteína tem um papel importante no 
desenvolvimento de certos tipos de cancro, demonstrando alterações relativamente aos 
seus níveis de expressão e localização na superfície celular, assim como no seu grau de 
glicosilação, desde as primeiras alterações tumorais verificadas ao nível da célula. Com 
esta abordagem, pretende-se tornar mais específica e intensa a acumulação deste tipo de 
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partículas em tecidos cancerígenos, que ocorre devido à arquitectura vascular anómala, 
caracterizada por amplos espaços entre as células endoteliais. A referida acumulação de 
nanopartículas em tecidos tumorais é devida à sua dimensão reduzida que lhes permite 
extravasar pelos espaços endoteliais aumentados, à drenagem linfática ineficaz dos 
tecidos tumorais e ao longo tempo de permanência na circulação sanguínea que aumenta 
a probabilidade e a frequência do extravasamento. 
 Utilizaram-se quelatos de gadolínio como agente de contraste, pois o contraste 
positivo produzido por este ião paramagnético em imagens de RM ponderadas em T1 é 
mais fácil de assinalar que o contraste negativo induzido pelos contrastes 
superparamagnéticos em imagens ponderadas em T2. A quantidade relativamente 
elevada de quelatos de gadolínio encapsulada nas micelas, a retenção e acumulação 
destes transportadores na lesão tumoral vão aumentar a concentração local do meio de 
contraste. Este fenómeno resultará numa amplificação da intensidade de sinal emitida 
pela lesão tumoral, o que aumenta a sensibilidade para a sua detecção, mesmo quando 
apenas existe um número limitado de células alteradas. Enquanto se aumenta a 
biodisponibilidade local do meio de contraste, diminui-se a concentração total de 
contraste necessária para a obtenção de imagens com acuidade diagnóstica. 
Mediante o descrito, este trabalho foi desenvolvido com o intuito de testar o 
mecanismo de resposta das micelas à diminuição do pH, de perceber se os quelatos de 
gadolínio hidrofóbicos produziam um aumento de contraste em imagens de RM 
compatíveis com aplicação clínica, de testar a toxicidade in vitro dos quelatos de 
gadolínio livres ou encapsulados nas micelas e de avaliar a especificidade deste novo 
sistema para as células-alvo. Para este fim sintetizaram-se micelas com complexos de 
gadolínio, micelas com o fluoróforo 1-metilpireno encapsulado e micelas bioconjugadas 
com o anticorpo anti-MUC1 e com fluoróforo encapsulado. As nanopartículas foram 
caracterizadas por Dispersão Dinâmica de Luz (DLS). A distribuição de tamanho 
mostrou que as micelas com 1-metilpireno encapsulado têm cerca de 24 nm de 
diâmetro. Obtiveram-se curvas de calibração para os quelatos de gadolínio e para o 
fluoróforo para se estimar a concentração total de cada um dos compostos numa dada 
suspensão de micelas. Demonstrou-se a capacidade destas micelas para se 
desintegrarem em pH ácido e libertarem o agente de contraste através da aquisição de 
imagens de duas amostras com micelas com meio de contraste encapsulado e com 
diferente pH, num equipamento de RM de 1.5 T. Outra experiência semelhante foi 
realizada, através da injecção intramuscular de micelas com meio de contraste 
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encapsulado em ambos os membros posteriores de um ratinho. Sendo que, previamente 
havia sido injectado uma solução ácida no membro posterior direito. As imagens da 
primeira experiência demonstraram um aumento da intensidade do sinal proveniente da 
amostra com pH baixo, enquanto a amostra com pH neutro não demonstrou qualquer 
alteração de sinal relativamente ao meio envolvente. Relativamente à segunda 
experiência, verificou-se que a intensidade do sinal proveniente do membro direito era 
superior à do no membro esquerdo. A citotoxicidade dos complexos de gadolínio foi 
observada in vitro através de ensaios de MTT em diferentes linhas celulares de cancro. 
Verificou-se que a encapsulação dos complexos de gadolínio nas micelas diminuiu 
significativamente a sua toxicidade comparativamente com o complexo livre. O valor de 
IC50 para estes quelatos de gadolínio variou entre 10.2 e 12.8 μM consoante a linha 
celular em estudo. As experiências de verificação da especificidade das micelas 
bioconjugadas com C595 para linhas celulares de carcinoma mamário que expressavam 
MUC1 foram realizadas através de citometria de fluxo e microscopia de fluorescência. 
As micelas tinham 1-metilpireno encapsulado para facilitar a sua observação por ambos 
os métodos. Utilizaram-se como controlo células estromais da medula óssea de ratinho. 
Observou-se que as partículas conjugadas ao anticorpo mostraram maior afinidade para 
as células que expressavam MUC1 do que as partículas sem anticorpo. A expressão de 
MUC1 nas linhas celulares utilizadas foi comprovada através de RT-PCR semi-
quantitativo, PCR em tempo real, Western blotting e citometria de fluxo. 
Os resultados obtidos demonstraram que estas micelas têm potencialidade para ser 
utilizadas em RM como agente de contraste, pois, relativamente aos agentes de 
contraste actualmente utilizados, combina a capacidade de acumular passivamente 
(devido à dimensão) e activamente (devido à bioconjugação com o anticorpo) em 
tumores que expressem a proteína MUC1. Além disso, possibilita a amplificação do 
sinal da imagem de RM em microambientes com pH relativamente ácido, que são 
habitualmente característicos de lesões cancerígenas. 
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1. NANOTECHNOLOGY 
Nanotechnology has emerged in the last few years as a new multidisciplinary scientific 
field, which not only benefits from but also has an impact on such diverse domains as 
chemistry, physics, electronics, optics, energy, materials science, space technology and 
biomedicine (Porter & Youtie, 2009; Choi & Baker, 2007). Nanoscience offers the 
exceptional possibility to produce nanoscale devices with approximately 1–100 nm and 
containing multiple integrated properties (Liu, Kiessling, & Gatjens, 2010; Yezhelyev, 
Gao, Xing, Al-Hajj, Nie, & O’Regan, 2006). 
 
1.1. NANOPARTICLES IN MEDICINE  
Great progress has been made regarding nanomaterial applications to medicine. These 
compounds have not only been tested in in vitro experiments but also been applied 
clinically (Tiefenauer, 2007). The development of this research area will provide 
extraordinary opportunities for future individualized diagnostic strategies and 
therapeutic approaches for humans (Liu et al., 2010). 
Nanoparticles are complex compounds made of multiple molecules and 
polymers that may present single or multiple functions (Bulte & Modo, 2008). They 
have been developed as contrast agents for medical imaging, for therapeutic 
applications such as target carriers for drug controlled release and for gene delivery 
(Kairemo, Erba, Bergström, & Pauwels, 2008; Peer et al., 2007).  
An area under intensive research is the application of nanoparticles for 
molecular imaging (Young-wook, Jae-Hyun, & Jinwoo, 2007). Molecular imaging is an 
interdisciplinary research field, which covers chemistry, biology, pharmacology, and 
medicine, aiming to detect early, to visualize and to characterize physiological and 
disease processes in vitro and in vivo (Weissleder & Mahmood, 2001). This application 
provides valuable clinical information to help guiding therapy against a variety of 
diseases, such as cancer (Mankoff, 2007). The issue of early cancer diagnostics has been 
the object of much research. Several types of nanoparticles with variable characteristics 
have been engineered to optimize cancer detection through noninvasive imaging 
modalities, such as magnetic resonance imaging (MRI), computed tomography, 
ultrasound, positron emission tomography, single photon emission computed 
tomography and near-infra-red fluorescence imaging (Weissleder, 2002).  
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Critical features for successful preparation and application of nanoparticles to 
biological environments are reproducibility of synthesis method, creation of well-
defined nanoparticles with monodispersity populations, low immune system reactions 
and reduced cytotoxicity and elimination from the biological system (Choi & Baker, 
2007). Novel challenges have also emerged, such as the elimination of nonspecific 
uptake of nanoparticles by macrophages and other cells of the reticuloendothelial 
system (RES); the development of more specific nanoparticles that target just molecules 
of interest, and the design of particles small enough to penetrate endothelial barriers 
(blood-brain barrier and dermal tight junctions). At the same time, nanoparticles should 
be able to maintain long-circulating blood half-lives, allowing accumulation at the target 
location and release of their contents to get a localized high drug/contrast agent (CA) 
concentration with far less systemic effects. Another new approach is the use of 
diagnostic ―smart‖ agents that behave as sensors and act in response to several 
biological phenomena (Bulte & Modo, 2008; Kairemo et al., 2008).  
Depending on the application intended, the surface of nanoparticles can be 
decorated with various molecules to avoid the recognition by the immune system and 
can be functionalized with targeting ligands to create specificity for a receptor of 
interest. Several molecule-specific ligands have been used, including antibodies and 
their fragments, aptamers, peptides, peptidomimetics, vitamins and carbohydrates ( 
Mulder, Strijkers, van Tilborg, Griffioen, & Nicolay, 2006; Allen, 2002). To target 
exclusively cancer tissues, several nanoparticles have been functionalized to bind tumor 
biomarkers such as transferrin receptors (Choi, Alabi, Webster, & Davis, 2010), folate 
receptors (Hong et al., 2008), ανβ3 integrin (Winter et al., 2003), epidermal growth 
factor receptor (EGFR) (Yan et al., 2009), human epidermal growth factor receptor 2 
(HER2) (T. Chen et al., 2009), prostate specific membrane antigen (Wang et al., 2007) 
and somatostatin receptors (Li et al., 2009). 
Despite the increasing diversity of nanoparticles, most can be classified into two 
major types: inorganic or organic. Inorganic nanoparticles have an inorganic core that 
confers specific fluorescence, optical, electronic and magnetic properties. The surface 
core is coated with a protective biocompatible organic layer that stabilizes the structure, 
avoids uncontrolled growth, aggregation and delays blood elimination of the 
nanoparticles (Yezhelyev et al., 2006). Some examples are quantum dots, 
superparamagnetic, silver, gold, silica and calcium nanoparticles (Tiefenauer, 2007; 
Xing, Chang, & Kang, 2010). These nanoparticles are disadvantageous for systemic 
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cancer cell targeting, because they are neither biodegradable nor small enough to be 
efficiently cleared from the blood through the kidneys, and can thus accumulate in the 
body and cause long-term toxicity (Peer et al., 2007). Organic nanoparticles such as 
liposomes, micelles, dendrimers, carbon nanotubes and other polymers are composed of 
organic materials (Lee, MacKay, Fréchet, & Szoka, 2005; Yezhelyev et al., 2006). 
These nanoparticles have been extensively used as drug and CA carriers. They present 
an increased hydrophilic and hydrophobic content, bio-availability, a high surface-area-
to-volume ratio, which allows attachment of several targeting ligands to the surface, and 
have shown an efficient accumulation at pathological locations (Kairemo et al., 2008; 
Peer et al., 2007). 
Polymers are the most commonly explored materials for the design of organic 
nanoparticles. These biomaterials are long-chain molecules composed of a large number 
of small repeating units (monomers), and can be derived from natural sources or from 
organic synthesis (Cooper, Visser, Hergenrother, & Lamba, 2004).The methods of 
synthetic polymer preparation can be classified into two groups: addition 
polymerization and condensation polymerization. In addition polymerization, 
monomers have to be activated by an initiator (free radicals, cations, anions or catalysts) 
to react through the stages of initiation, propagation, and termination to form the final 
polymer. For condensation polymerization, the monomers contain functional groups, so 
the initiator is not required. Two monomers react to form a covalent bond, usually with 
elimination of a small molecule such as water, hydrochloric acid, methanol, or carbon 
dioxide. The reaction is continuous until one of the reactants finish (Park & Lakes, 
2007, pp.173-177). The choice of polymerization method strongly affects the polymer 
obtained. For example, considering addition polymerization of free radicals, the 
molecular weights of the polymer chains are difficult to control while in anionic 
polymerization the molecular architecture can be easily controlled. Recent methods of 
living free radical polymerizations called atom transfer radical polymerization and 
Reversible Addition-Fragmentation chain Transfer (RAFT) polymerization have been 
used to create amphiphilic block copolymers with well-defined structures. These 
methods proved to achieve low polydispersity indexes, which enable well-controlled 
composition, size and morphology of polymeric micelles ( Zhang, Zhang, Wen, Li, & 
Li, 2008; Stenzel, 2008).  
Polymers can be classified as homopolymers, which are composed by one type 
of repeat unit, or as copolymers, which are made by two or more types of repeat units. 
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Regarding copolymers, the structure of polymer chains can be alternating (monomers 
alternate along the chain), random (monomers are randomly distributed along the 
chain), graft (main chain is made up by one type of monomer to which are bounded 
small chains of another monomer), or block copolymers (the polymer chain is formed 
by blocks of each monomer). As block copolymers have separate segments they display 
the individual features of each homopolymer (Cooper et al., 2004). 
 
1.1.1. MICELLES 
Micelles are self-assembling nanosized colloidal particles with a hydrophobic core and 
hydrophilic corona (Figure 1) (Torchilin, 2007). There are several composites able to 
form micelles. However, amphiphilic block copolymers have received a great deal of 
attention. These polymers are composed by hydrophilic and hydrophobic monomer 
units. These molecules form micelles spontaneously when they are dissolved in 
selective solvents, under a narrow concentration interval (critical micelle concentration) 
and temperature (critical micellization temperature) (Palivan, Vebert, Axthelm, & 
Meier, 2006; Jones & Leroux, 1999). Polymeric micelle formation involves a decrease 
of free energy in the system due to elimination of hydrophobic blocks from the aqueous 
environment. The hydrophobic region of the amphiphilic polymer forms the micelle 
core, while the hydrophilic region composes the micelle corona that stays in contact 
with water (Kwon & Okano, 1999).  
  
Figure 1 - Micelle structure. Polymeric micelles are composed by a hydrophobic core (orange) and a hydrophilic 
corona (green). Adapted from (Peer et al., 2007). 
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Polymeric micelles have been successfully used as drug carriers due to their high 
stability in vitro and in vivo and improved bioavailability of the content. Micelle content 
can be released by surface erosion, by diffusion through progressive degradation of the 
hydrophobic core, or in response to environment (pH, temperature, or salt concentration 
sensitivity) (Rutkaite, Swanson, Li, & Armes, 2008). In addition, their smaller size 
compared to other particulate carriers allowed a superior permeability across 
physiological barriers and improved biodistribution (Nakamura, Makino, Okano, 
Yamamoto, & Yokoyama, 2006; Hong et al., 2008; Maeda, Wu, Sawa, Matsumura, & 
Hori, 2000). The use of copolymers having a poly (ethylene glycol) (PEG) extends the 
micelle half-life in blood. A direct correlation between the longevity of a particulate 
drug carrier in the circulation and its ability to reach its target site has been observed on 
multiple occasions ( Maeda, Sawa, & Konno, 2001; Torchilin, 2001). Micelles have 
also a reasonably narrow size distribution, and are very easy to prepare and to load drug 
or CA (Heller & Hoffman, 2004). By changing the copolymer chain size and chemical 
nature, the type of solvent used to dissolve the copolymer, and the critical micelle 
concentration of the copolymer, it is simple to modify the shape and size of polymeric 
micelles. Several formulations of drug-loaded micelles are currently at different stages 
of preclinical and clinical trials (Torchilin, 2007).  
The transport of CA by micelles is a relatively new approach, which have been 
experimented just for diagnostic/imaging or for monitoring the drug delivery by 
micelles (Liu, Zeng, & Allen, 2007; Zhang et al., 2008). 
A promising approach on medical imaging is the use of stimuli-sensitive 
micelles whose degradation and resultant content release is due to pH or specific 
temperature values (Nakamura et al., 2006; Torchilin, 2007). Stimulus-sensitive 
micelles are made of ―smart‖ polymers, which respond to slight alterations in physical, 
chemical or biochemical environmental conditions with significant changes in their 
physical properties (Hoffman, 2004). Consequently, micelles composed by these special 
polymers are able to dissociate the core and release their content only under certain 
pathological features (Palivan et al., 2006). Several approaches using pH-sensitive 
micelles, which release their content in conditions of low tumor cell pH, have been 
studied and used successfully to improve the efficiency of chemotherapy and to 
decrease the side effects and toxicity of free chemotherapeutics (Lee, Na, & Bae, 2003; 
Lee, Na, & Bae, 2005; Gillies & Fréchet, 2005; Hrubý, Konák, & Ulbrich, 2005). 
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1.1.1.1. PH-SENSITIVE MICELLES FOR EARLY CANCER DETECTION 
This new kind of pH-sensitive nanoparticles seemed to be a very promising approach 
for early cancer detection because they disassemble exclusively in a specific pH value, 
have proven to be stable and are efficient carriers for hydrophobic drug molecules. 
Therefore a new class of nanoparticle-based CA has been developed.  
The proposed pH-sensitive polymeric micelles are able to encapsulate a large 
number of CA molecules (hydrophobic Gadolinium ion [Gd(III)] chelates) during its 
self-assembly from simple building blocks (Poly(ethylene glycol-b-trimethylsilyl 
methacrylate). The pH-sensitive mechanism of the designed polymeric micelles is 
generated by amphiphilic polymer silicon moieties that can be cleaved in a slightly 
acidic environment. This cleavage turns the polymer hydrophilic, which triggers micelle 
disassembly and release of its content (Figure 2). This pH-sensitive amphiphilic diblock 
copolymer was synthesized by RAFT polymerization from trimethylsilyl methacrylate 
using α-(O-ethylxanthate)-ώ-methylPEG 2’000 as a macro-chain transfer agent (macro-
CTA), and a monomer to macro-CTA ratio of 45:1. Azobis-isobutyronitrile (AIBN) (1 
mol% of the monomer), was used as radical initiator (Chiefari et al., 1998). The CA was 
synthesized and characterized via well known synthesis routes to generate hydrophobic 
Gd(III) complexes with ligands such as bipyridine (Bechara, Leygue, Galaup, Mestre, & 
Picard, 2009). 
Figure 2 – Schematic representation of amphiphilic diblock copolymer 
synthesis and micelle pH-sensitive disaggregation. Synthetic approach for the 
synthesis of poly(ethylene glycol-b-trimethylsilyl methacrylate) and schematic 
representation of its self-assembly into micelles and their disaggregation due to pH 
decrease. 
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These polymeric micelles were designed to remain intact during circulation and 
if the target is absent, the CA remains switched-off until their removal from the system. 
However if micelles reach the target site (cancer tissue), they disassemble due to low 
pH. When micelles are intact, they restrict water access to the hydrophobic Gd(III) 
chelates that are located in the micelle core. Consequently, the relaxivity of nearby 
water molecules remain unchanged, however when these Gd(III) complexes are 
released from the micelle core, they will have access to water molecule protons and thus 
reduce the longitudinal magnetization time (T1) of the water surrounding the targeted 
tissue. This new approach will therefore provide the medicine with better tools to 
understand the causes and mechanisms of disease and the associated structural and 
functional alterations. 
The size distribution profile of the novel micelles (with encapsulated 1-
methylpyrene) was found to be around 24 nm (Figure 3), as measured by dynamic light 
scattering (DLS) (Figure 3-A). These micelles were also visualized under transmission 
electron microscopy (TEM) (Figure 3-B) and the size matches the values obtained from 
DLS. 
 
To establish the amphiphilic aggregation of the copolymer and its 
disaggregation, with parallel tracer release under pH change, it was used the 1-
methylpyrene fluorescence spectrum. When 1-methylpyrene is dissolved and 
encapsulated inside micelles, it reaches a threshold concentration (104 M) that induces 
the formation of excimers, which have a different emission wavelength than 1-
Figure 3 – Micelle size characterization. (A) Dynamic Light Scattering results 
showing the size distribution profile of 1-methylpyrene loaded polymeric micelles. (B) 
Transmission electron microscopy of 1-methylpyrene loaded polymeric micelles after 
the self assembly of poly(ethylene glycol-b-trimethylsilyl methacrylate), bar scale 
50nm. 
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methypyrene monomers. The monomer emission occurs in less concentrated solutions 
and in aqueous solutions due to the low solubility of 1-methylpyrene. The emission 
spectrum of 1-methylpyrene-loaded micelles in a pH=7 aqueous solution revealed both 
monomer (at 375 nm) and excimer (at 480 nm) emission bands, indicating that micelles 
existed in the aqueous solution. On the other hand, the emission spectrum of 1-
methylpyrene-loaded micelles in a pH=5 aqueous solution showed only the monomer 
emission band, indicating that nanoparticles were decomposed and had release their 
content. The release causes contact of excimer with water and consequent decrease of 
the threshold concentration required to form them (Figure 4). 
 
After proving the ability of these nanoparticles to release their content in acidic 
conditions, we demonstrated by 
1
H Magnetic Resonance (NMR) Spectroscopy that the 
CA (tetraaquodichloro(4,4'-ditBu-2,2'-bipyridine)gadolinium(III) chloride) encapsulated 
within the micelle core was shield from water molecules in solution (Figure 5). This 
conclusion stems from the observation that the T1 measured in a pH=7 aqueous solution 
with Gd(III) complex-loaded micelles was 3.4 seconds, while at pH=5 the T1 time 
obtained was 1.7 seconds. At pH=7, intact polymeric micelles restrict the water access 
to the Gd(III) complexes and the T1 value is the same as the T1 measured in pure water 
(switched-off state). In contrast, micelles disassembled due to low pH (similar to those 
found in cancer tissue) and the water molecules had accessed and exchanged with 
Gd(III) complexes, thus significantly decreasing the T1 of the aqueous solution 
surrounding these nanoparticles (switched-on state). 
 
Figure 4 - Spectroscopic proof of polymeric micelles formation and disassembled with parallel release of 1-
methylpyrene due to low pH. At pH=7 the polymeric micelles are stable as the excimer band (480 nm) holds. 
However at pH=5.5 only the monomer emission (375 nm) stands due to complete release of 1-methypyrene. 
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Because the existing imaging techniques are generally unsatisfactory for many 
molecular imaging applications, it is important to develop high-performance imaging 
systems capable of identifying detailed biological processes at the molecular and 
subcellular levels. Currently, MRI is one of the most powerful medical diagnostic tools 
available mainly due to its high spatial resolution and by the fact that physiological and 
anatomical information can be acquired simultaneously (Li, Fraser, & Meade, 1999; 
Medarova, 2009). However, in terms of sensitivity MRI lags behind other tools 
(Massoud & Gambhir, 2003). To overcome this hurdle, several attempts have been 
made to improve the sensitivity of MRI using CAs. With the increasing ability of 
nanotechnology to create devices at the cellular and molecular scale, more powerful 
imaging CAs for MRI such as superparamagnetic particles of iron oxide (SPIO) and 
magnetodendrimers nanoparticles have developed. SPIO have gained great attention for 
molecular MRI and has been experimentally and clinically used to detect infarction, 
inflammation, angiogenesis, primary malignant lesions, and lymph node metastasis 
(Priest et al., 2006; Russell & Anzai, 2007; Gambarota et al., 2006; Corot, Robert, Idée, 
& Port, 2006). Although much progress has been made to develop these nanoparticles 
during the past few years, their successful use has been limited to in vitro systems, 
Figure 5 - Schematic representation of switch off/on mechanism. 
Relaxometric experiment that measures the T1time before and after the 
release of the contrast agent from the polymeric micelle using NMR. 
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except for a few in vivo cases. These difficulties lie on two factors: poor MRI contrast 
effects and limited stability and biocompatibility under in vivo conditions. 
The new micelles have therefore a great potential to be used as CA for MRI. 
They present the advantage over other CAs of imaging cancer tissues only and not 
normal cells, because they expose Gd(III) chelates to the aqueous surroundings and 
enhance the relaxivity of the paramagnetic metal only under characteristic low pH 
cancer environments. These micelles should increase the half-life in blood of the Gd(III) 
complexes, by providing a protection from the outside elements via their encapsulation 
within their the core. Furthermore, this CA system will provide an increase in sensitivity 
through signal amplification of the targeted tissue. The signal is amplified via the 
massive amount of the CA that has been encapsulated within these micelles. This last 
feature allows detecting cancer in very early stage when cancer related molecular and 
cellular changes are minor, and reduces the amount of CA required for imaging. 
 
2. MAGNETIC RESONANCE IMAGING 
MRI is a non-invasive medical imaging technique with several advantages over others, 
such as the ability to obtain direct multiplanar images and physiological data and to 
avoid ionizing radiation. In addition, MRI allows submillimeter spatial resolution, 
which is the capacity to identify an object as a separate and different element from 
another object. It has an excellent contrast resolution, which is the ability to differentiate 
tissues with low contrast, and has a good sensitivity, which reflects how well an 
imaging system can detect slight differences in anatomy (Bushong, 2003, pp.3-15). 
 
2.1. BASIC PHYSICAL PRINCIPLES 
The human body is constituted by approximately 80% of hydrogen atoms. MRI collects 
the signal from the nuclei of hydrogen atoms to produce images (Bushong, 2003, pp.3-
15). The proton of the hydrogen atom has a spin movement, which means that it turns 
around an axis. The orientation of its rotational axis is normally random during the 
rotation movement. Since the proton is a mass with an electrical charge in movement, it 
has a magnetic moment and acts as a bar magnet (Weishaupt, Kochli, & Marincek, 
2006, pp.1-5). When the protons are exposed to a strong external magnetic field (B0) 
they align themselves approximately with the direction of B0 in two possible ways: 
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parallel or anti-parallel (Figure 6). These alignments imply distinct levels of energy, so 
the one that takes less energy, the parallel alignment, is the one which has a slight larger 
number of protons (Westbrook & Kaut, 2000, pp.1-11). The protons have now a wobble 
movement, called precession. This precession movement has a characteristic speed, 
which is positively correlated with the strength of the applied B0 and is named 
precession frequency or Larmor frequency (McRobbie, Moore, Graves, & Prince, 2006, 
pp.137-144). When the protons are in precession movement, their individual magnetic 
moments add together and cancel each other as some protons align parallel and others 
antiparallel. However, there are more protons aligned parallel than antiparallel. 
Consequently, some magnetic moments are not cancelled and the resultant 
magnetization is represented by a vector in the z-direction, aligned with B0 direction, 
called net magnetization vector (M) (Brown & Semelka, 2003, pp.1-9). This vector 
originates the signal for the MR image but while it has the same direction of B0 it is 
impossible to measure it directly. For this purpose M has to be perpendicular to B0. To 
obtain this, the system needs to have an energy supply, so an electromagnetic wave with 
the same frequency as the Larmor frequency will be applied to the system (McRobbie et 
al., 2006, pp.137-144).  
 
 
 
The radiofrequency (RF) pulse, emitted from a radio antenna, called coil, will 
perturb the stable aligned precession movement of the protons and make them obtain 
energy, a process named resonance (Bushong, 2003, pp.3-15). The energy transfer has 
two consequences on the protons: changes the energy state of each proton and some will 
Figure 6 – Schematic representation of hydrogen nuclei behavior under the influence of a magnetic field (B0). 
Protons usually spin with a random direction, however when applied B0, they aligned in two ways: parallel and 
antiparallel. As little more protons align parallel to B0, they create a longitudinal magnetization (M). Adapted from 
(Weishaupt et al., 2006, pp. 1-5).  
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raise to a higher level of energy, being into the negative z-direction (antiparallel to B0) 
and also makes the protons to precess in phase coherence, which means that they all 
have an equal position on the precession movement (McRobbie et al., 2006, pp.137-
144). These changes will traduce in a decrease of the longitudinal magnetization and in 
an appearance of a new magnetization in the xy-plane that is perpendicular to the 
direction of B0, called transversal magnetization (Figure 7). The transverse 
magnetization precesses around the z-axis, being a constant oscillating magnetic field, 
which induces a voltage varying at the Larmor frequency. This signal, known free 
induction decay (FID) will be collected as a radio signal emitted from the human body 
by a receiver coil and processed by computers, giving rise to the MR image (Nitz & 
Reimer, 1999). The MR signal is fluctuating and decreases with time due to the proton 
spin relaxation in order to get the original state and is represented by time constants 
called relaxation times (Westbrook & Kaut, 2000, pp.1-11). 
 
 
Figure 7 – Schematic representation of the behavior of the net magnetization vector, M, after the system 
received energy from a RF pulse. The RF pulse tips some protons to a higher level of energy and make the protons 
to precess is phase. As a consequence there is a decrease in longitudinal magnetization and appear a new transverse 
magnetization vector in xy plane, which rotate around z-axis. Adapted from (McRobbie et al., 2006).   
 
2.2. RELAXATION TIMES 
When the RF pulse is turned off, the system relaxes and returns to its lower state of 
energy, consequently the transversal magnetization diminishes until extinction 
(transversal relaxation) and the longitudinal magnetization increases until its original 
value (longitudinal relaxation) (McRobbie et al., 2006, pp.148-153).  
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Longitudinal or spin-lattice relaxation happens due to energy transfer for the 
environment or lattice and the time constant that represents how quickly is the recovery 
of longitudinal magnetization is named longitudinal magnetization time or T1. This time 
constant is dependent on the strength of B0 and the inner movement of the molecules 
(Brownian motion). Transversal or spin-spin relaxation is caused by internal magnetic 
field variations such as different proton precession frequencies because of 
inhomogeneity in B0 and the influence of the magnetic field of each proton in the nearby 
nuclei. The different precession frequencies cause the protons to be out of phase. This 
will cause the decrease of transversal magnetization and the constant time which 
describes this process is the transversal relaxation time or T2 (Brown & Semelka, 2003, 
pp.21-31). These two relaxations times T1 and T2 represent two independent processes 
which occur at the same time (Bushong, 2003, pp.64-71). 
 
2.3. MAIN TYPES OF IMAGE CONTRAST 
Contrast in MR images is reached based on tissue differences in T1, T2, and proton 
density (PD). These parameters are intrinsic features of biological tissues which using 
different RF pulse sequences can produce an image intensity that can be weighted with 
respect to T1, T2 or PD (Figure 8) (Nitz & Reimer, 1999). As these parameters are very 
different from one tissue to another, this allows soft-tissue discrimination and diagnostic 
potential of MRI. To create an MR image, a slice of the body has to be excited with 
more than one RF pulse (a succession of RF pulses is a pulse sequence) and the emitted 
signal recorded many times. The repetition time (TR) is the interval between two 
successive excitations of the same slice and consequently the duration of the relaxation 
period between two excitation pulses. The echo time (TE) is the time-period between 
application of the RF pulse and the collection of the MR signal (Weishaupt et al., 2006, 
pp. 11-20). The generation of T1-, T2-, or PD-weighted images depends on the TR and 
TE values (Nitz & Reimer, 1999). 
The time constant T1 is short when the change of energy is efficient (the lattice 
has precession frequencies near the Larmor frequency). When the molecules in the 
environment do not move at the Larmor frequency, the protons are not able to send its 
energy fast to the surroundings, so they will be slower to return to their lower energy 
level. Consequently the longitudinal magnetization will take a long time to recover, and 
the T1 time will be long (Westbrook & Kaut, 2000, pp.12-20). To get advantage of this 
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biological characteristic one can use a short TR to create a difference in signal intensity 
between different tissues. This difference will be possible because the tissues with short 
T1 will recover faster than others with long T1. However, if a long TR is used, all tissues 
recover its longitudinal magnetization and the signal differences disappear. So the 
resulting MR image of a short TR is classified as T1-weight image (T1WI) (Figure 8-A), 
since tissue contrast is mostly created by their difference in T1 times. Tissues with short 
T1 appear bright and others with a long T1 present a weak signal (Nitz & Reimer, 1999). 
The T2 time constant represents the velocity of decrease in transversal 
magnetization vector after the RF pulse excitation. When the image contrast is almost 
dependent of the T2 times of the tissues, the image is classified as T2-weighted image 
(T2WI) (Figure 8-B). If a long TE is used, the tissues show different signal intensities 
and a good contrast on the MR image. The tissues with short T2 lose their transversal 
magnetization and appear dark, while tissues with a long T2 maintain the magnetization 
longer and produce a stronger signal appearing bright (Nitz & Reimer, 1999). 
PD is the number of hydrogen atoms in a particular volume. To get a PD-
weighted image (Figure 8-C) the influence of the other two parameters, T1 and T2, has 
to be suppressed. To this end, a long TR and a short TE is used, so that the collected 
signal is neither T1WI nor T2WI, but mostly influenced by differences in proton density. 
Thus, tissues with large content in hydrogen emit a stronger signal (McRobbie et al., 
2006, pp.32-36). 
 
 
Figure 8 - Sagittal images of the knee. (A) T1-weight image. (B) T2-weight image. (C) PD-weight image. Adapted 
from (McRobbie et al., 2006, pp.32-36). 
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3. MAGNETIC RESONANCE IMAGING WITH CONTRAST AGENTS  
MRI easily creates a distinction between different tissues based on differences in T1, T2 
and PD. However, healthy and pathological tissues as well as distinct diseases show 
similar magnetic moments producing a poor image contrast. To get a better anatomical 
differentiation and to improve sensitivity, CAs are used. Due to their physico-chemical 
properties, CAs induce different effects on image signal intensities by modifying the 
intrinsic contrast properties of biological samples (Weishaupt et al., 2006, pp.103-123). 
CAs can also increase image quality, allow higher resolution, and provide kinetic 
information about an enhanced lesion (McRobbie et al.,2006, pp.42-44). 
CAs act by shortening T1 and T2 relaxation times, however, some tracers 
decrease specially T1 time. Consequently, tissues with a short T1 appear bright on 
T1WIs. These CAs are called positive because they enhance the image signal. They are 
also classified as T1 CAs because effects of lower concentrations are easily observed on 
T1WIs. On the other hand the contrasts which have a greater change in T2 time of 
tissues are called negative, because they cause a decrease in image signal (Figure 9-B). 
They are T2 CAs, because their effect is clearly evident on T2WI (Gandhi, Brown, 
Wong, Aguirre, & Sirlin, 2006) 
 
 
The present thesis is about a T1 CA based on Gd(III) chelates. Therefore the 
mechanism of action and classification will be detail describe for Gd(III)-based CAs. 
Figure 9 – Negative contrast provided by uptake of SPIO by Kupffer cells (RES). (A) Axial T2WI obtained 
before the administration of SPIO. (B) Axial T2WI after injection of SPIO demonstrates signal image decrease 
on normal liver parenchyma due to uptake of iron oxide nanoparticles (black arrow) and maintenance of the 
enhancement by metastatic liver lesion (white arrow), which tumor cells replaced kupffer cells. Adapted from 
(McRobbie et al., 2006, pp.42-44). 
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3.1. MECHANISM OF SHORTENING T1 AND T2 TIMES  
In the human body, the water molecules possess a rotation movement faster than 
Larmor frequency, consequently their relaxation is inefficient and they have a long T1. 
The spin molecules used as CA have a high magnetic moment and in close contact with 
the protons of water they will induce a fluctuation in the neighboring magnetic fields 
near the Larmor frequency. This influence will facilitate the water molecules to 
decrease the energy that have previously gained from the RF pulse. Therefore the 
relaxation time T1 of the neighbor water protons is reduced and water will appear bright 
in a T1WI. There is also a decrease of T2 due to the magnetic moments of unpaired 
electrons, which alter the local magnetic field strength, causing a faster dephasing of the 
protons (Westbrook & Kaut, 2000, pp.193-197). The magnetic field inhomogeneity 
created by Gd(III) has a very small distance of action, however the newly affected 
protons will also exchange with other protons further away from Gd(III). So there is an 
overall reduction of T1 and T2 (Gandhi et al., 2006).  
The interference in the local magnetic field strength is due to dipole-dipole 
interactions between the unpaired electron spins or protons of the CA and the 
neighboring excited hydrogen nuclei of the water, fat, or protein molecules which 
compose the tissue. Therefore, a fraction of the action mechanism of the CA is based on 
the electron shell and not simply due to nuclear interactions. The magnetic moments of 
the electrons are much higher than those of protons, thus the electron shell contains 
powerful paramagnetic properties. The relaxation produced by contrast on surrounding 
tissues is a result of inner-sphere and outer-sphere effects. The first one is caused by the 
relaxation of the hydrogen nuclei of water molecules directly bound to the paramagnetic 
ion of the CA, and the second is caused by interactions between paramagnetic ions and 
closely diffusing water molecules (McRobbie et al., 2006, pp.162-166).  
The interaction efficiency of CA with nearby water molecules is translated by 
the measure of relaxivity or relaxation rate (R1 and R2). This parameter is the inverse of 
the relaxation time, so it is determined by measuring T1 or T2, respectively, in a one 
molar solution. A higher relaxivity reflects an efficient interaction between the CA and 
the water protons, thus a faster relaxation of the protons and an increase in signal on 
T1WI (Weishaupt et al., 2006, pp.109-112). 
 
Self-assembled nanoparticles as new smart contrast agents for magnetic resonance imaging  2010 
T. Simão  18 
3.2. CONTRAST AGENTS FOR T1WI 
Paramagnetic substances are atoms or molecules which have a strong magnetic moment 
due to unpaired electrons in their outer electron shells or unpaired nucleons in their 
atomic nuclei (Westbrook & Kaut, 2000, pp.193-197). When these paramagnetic 
materials are under an external magnetic field, their magnetic moments align, add up 
and create a positive and strong net magnetization, while most body tissues, which are 
diamagnetic, become only weakly magnetized. Some metal ions that can be used as CA 
are Gd(III) and Manganese (II) and Manganese (III) 
 
(Kozlowska et al., 2009).  
Gadolinium belongs to the lanthanide series of rare earth elements. It has seven 
unpaired electrons, and therefore very strong paramagnetic properties (Que & Chang, 
2006). Free Gd(III) is toxic because its diameter is close to that of calcium ions. Indeed, 
gadolinium ions bind to calcium channels, preventing binding of calcium ions. For this 
reason Gd(III) cannot be used in their elemental state but have to be chelated to a 
ligand. Some examples of ligands used for complexing the Gd(III) are DTPA, DOTA, 
DTPA-BMA, HP-DO3A. These ligands reduce significantly Gd(III) toxicity and 
influence the pharmacokinetics of the complex. Several Gd(III) formulations are 
available for commercial use and others are under experimental scrutiny (Weishaupt et 
al., 2006, pp.107-109). 
 
3.2.1. NONSPECIFIC Gd(III)-BASED CONTRAST AGENTS 
The most frequent CAs used in clinical MRI are small molecule Gd(III) chelates that 
can distribute uniformly to all perfused tissues throughout the vasculature, and can 
diffuse across endothelial wall vessels into the extracellular spaces (Gandhi et al., 2006; 
Gillies, Raghunand, Karczmar, & Bhujwalla, 2002). These molecules are however too 
large to cross the blood-brain barrier, except when this is disrupted by pathological 
conditions (e.g. primary tumors and metastasis). In these settings, low molecular weight 
contrast agents (LMWCA)s can enter and accumulate in the affected brain tissue, 
resulting in increased visibility of the lesion. After systemic body distribution, these 
tracers are rapidly eliminated by kidneys (Padhani, 2002).  
LMWCAs have been extensively used to improve tumor localization and 
characterization through dynamic contrast enhancement (DCE) MRI. Some examples 
are cancers of the breast (Turnbulla, 2009), liver (Goshima et al., 2009), bone (Reddick 
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et al., 2001), lung (Hunter et al., 1998), pancreas ( Murakami, Nawano, Moriyama, & 
Onuma, 1998), prostate (Ocak et al., 2007), and brain (Padhani, 2002).   
DCE MRI consists in the acquisition of data after intravenous administration of 
CA. This method provides anatomical images and physiologic data such as a time-
enhancement curve, which is used to assess the enhancement of the lesion during the 
CA uptake and washout. Analysis of the curve shape aids the physician in the diagnosis 
of the tumor and in the distinction between a benign or malignant lesion (Rausch & 
Hendrick, 2006). A large portion of invasive breast cancers usually exhibit a quick and 
strong enhancement, and this is followed by either stabilization or fast loss of the signal 
intensity. On the other hand, benign lesions show a weaker but continuous 
enhancement. Contrast enhancement analyses are an excellent diagnostic tool for breast 
cancer in that more than 90% of breast cancers lesions show a strong enhancement 
(Kuhl, 2007). However, contrast enhancement is nonspecific because of considerable 
common contrast enhancement features between benign and malignant lesions (Rausch 
& Hendrick, 2006). For this reason, LMWCAs showed a high sensivity for tumor 
detection (e.g. breast tumors) but lack of specificity (Mattrey & Aguirre, 2003). 
LMWCAs are not taken up by particular organs, do not target specific tissues or 
pathological areas, and do not respond to the cellular microenvironment. They enhance 
all vessels and high vascular tissues (Figure 10-B). Thus only lesions with significant 
blood flow volumes can be distinguished by MRI, making it almost impossible the 
detection of primary cancer or metastasis when they measure just a few millimeters. 
Also, since these contrast agents leak through both normal and neoplastic vessels, it 
may be difficult to distinguish between normal and angiogenic vessels (Hartman et al., 
2008; McDonald & Choyke, 2003). These CAs have also a short half-life in blood 
(Mattrey & Aguirre, 2003) and a large part of administered CA is eliminated before 
images are taken. Therefore, in order to get informative images, a substantial quantity of 
CA needs to be injected in the patient, which may constitute at times a health risk for 
some patients (Nakamura et al., 2006). 
To overcome the drawbacks showed by LMWCAs, macromolecular weight 
contrast agents (MMWCA)s are in development. Some examples of MMWCAs are iron 
oxide particles and Gd(III) bound to larger molecules such as albumin, polylysine, 
dendrimers, micelles and liposomes (Padhani, 2002). 
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Figure 10 - Nonspecific image signal enhancement following administration of LMWCA. (A) Axial T1WI 
obtained before the administration of Gd(III) chelates,  image with no apparent lesion. (B) Axial T1WI after injection 
of CA demonstrates enhancement of a liver lesion (white arrow), blood vessels and high perfused organs (black 
arrows). Adapted from (Gandhi et al., 2006). 
 
These MMWCAs diffuse poorly or not at all through normal vessels, leaking 
only when the vessel wall is abnormal, as is the case for neoangiogenic vessels 
(Bhujwalla, Artemov, Natarajan, Ackerstaff, & Solaiyappan, 2001). MMWCAs are 
frequently used to blood pool imaging because of their long circulation times and 
slower diffusion as well as clearance from interstitial spaces (Gillies et al., 2002). This 
slower kinetics allows a better quantification of vascular leakage, thus helping to 
differentiate benign from malignant tumors. MMWCAs have therefore been reported to 
be better suited for assessment of microvasculature permeability of tumors lesions 
(Daldrup et al., 1998; Padhani,  2002). However, hyperpermeability to MMWCAs is not 
exclusive of cancer microvasculature, since it has also been observed in inflammatory, 
ischemic and transplant rejection tissue models (Mattrey & Aguirre, 2003). 
Chen and colleagues created a MMWCA for hepatocellular carcinoma detection 
in rats. They used self-assembled micelles made by poly lactic acid–PEG and 
commercial Gd(III)–DTPA. The Gd(III)–DTPA was absorbed onto the surface of the 
nanoparticles. This MMWCA provided better and prolonged image contrast effects than 
commercial LMWCA in liver, even with a lower dose of gadolinium per kilogram of 
body weight (Z. Chen et al., 2009). Zhang and colleagues reported a successful 
production of micelles based on biodegradable poly(L-glutamic acid)-bpolylactide 
block copolymer with DTPA-Gd(III) chelated to the micelle shell. This complex 
showed two-fold higher relaxivity than LMWCA (Zhang et al., 2008). Bertini and 
coworkers developed a MMWCA for detection of solid tumors. This probe consisted of 
PEG-stabilized paramagnetic liposomes, with Gd(III)–DTPA on their surface. This 
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MMWCA showed increased relaxivity compared to conventional LMWCA and 
achieved a prolonged visualization of neoplastic lesions in mice (Bertini et al., 2004). 
 
3.2.2. TARGETED Gd(III)-BASED CONTRAST AGENTS 
Since current MRI CAs have low specificity and since MRI has proven to be a valuable 
molecular imaging tool, efforts have been taken to develop targeted and specifically 
activated CAs. These tracers aim to target distinct molecules related with different 
pathologies, accumulate selectively in a exact biological site providing an increased 
local concentration of CAs, allow more specific diagnosis, and have the potential to 
characterize diseases at the molecular level in vivo (Aime et al., 2002; Kozlowska et al., 
2009). Targeted CAs identify specific cell types by internalization or interaction with 
proteins expressed on the cell surface (Lyons, 2005). Most MRI CAs used for molecular 
imaging are linear polymers and dendrimers conjugated to metal chelates as well as 
liposomes and micelles containing paramagnetic ions (Liu et al., 2010). 
An approach of target Gd(III)-based CA consisted of perfluorocarbon 
nanoparticles able to detect integrins expressed on neovasculature in nascent Vx-2 
rabbit tumors. In this experiment, a small arginine-glycine-aspartic acid-peptidomimetic 
was covalently attached to the nanoparticle. These nanoparticles showed specific signal 
enhancement in sites of tumor angiogenesis. Furthermore, the leakage in tumor vessels 
was greater than in muscle (Winter et al., 2003). Another research group successfully 
combined a long-circulating liposome with membrane-incorporated Gd(III)-chelates 
and a cancer specific antibody, 2C5, attached to the liposome surface (Erdogan, 
Medarova, Roby, Moore, & Torchilin, 2008). To detect tumor cell death after 
chemotherapy, Krishnan and colleagues produced specific CA based on Gd(III)-chelates 
conjugated to the C2A domain of synaptotagmin I, which targets the plasma membrane 
phospholipid phosphatidylserine expressed by apoptotic cells. This probe was able to 
identify tumor cell death in vivo (Krishnan et al., 2008).   
 
3.2.3. SMART Gd(III)-BASED CONTRAST AGENTS 
Targeted CAs may greatly improve the accuracy and extent of diagnostic imaging. 
However, another approach based on physiological activatable or stimulus-sensitive 
CAs, seems to offer a significant improvement of the MRI potential for disease 
detection. Unlike standard targeted agents, which enhance MR image constantly, smart 
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CAs change between two conformational states dependent on a certain stimulus. The 
change is detected as an alteration in signal, because one of the conformational states 
has low or no enhancement, the ―off state‖, and other has high enhancement, the ―on 
state‖. These stimulus-sensitive agents can be detected when switched from one state to 
another after exposure to a metabolic or physiological event in a specific molecular 
target (Lyons, 2005). Smart CAs have been built on Gd(III) systems because their 
relaxivity can be dictated by their environment. The numbers of water molecules in the 
first coordination sphere, the water exchange rate and the rotational correlation time 
have a strong effect on the relaxivity of the compounds and can be influenced by many 
factors. There are CAs responsive to metal ions such as calcium (Li et al., 1999), copper 
(Que & Chang, 2006) and zinc (Hanaoka et al., 2002), while others are sensitive to 
oxygenated hemoglobin (Aime et al., 1999b), the presence of radicals (Glogard, 
Stensrud, & Aime, 2003), or are enzimatically activated to provide a means of 
measuring enzyme activity and enzyme localization (Moats, Fraser, & Meade, 1997).  
The pH-sensitive CAs are of interest to tumor MRI imaging, because a common 
feature of cancerous tissues is a significantly lower extracellular pH as compared to 
healthy tissues. Thus, pH seems to be a promising parameter for detecting early stage 
cancer (Hartman et al., 2008; Gillies, Raghunand, Garcia-Martin, & Gatenby, 2004). To 
this aim, Zhang and colleagues created a pH-sensitive Gd(III) complex of a DOTA 
tetramide derivative. They observed an interesting behavior of the complex relaxivity 
versus pH. Indeed, starting from pH 4, the relaxivity first increased until pH 6 and then 
decreased until reaching a minimum at pH 8.5. It remained at this minimum between 
pH 8.5 and 10.5 and then increased again (Zhang, Wu, & Sherry, 1999). Aime and 
coworkers reported a pH-sensitive CA with Gd(III)-chelates and ornithin residues. The 
chelates were conjugated to the amino acid chain via squaric esters, which readily reacts 
with amines. At low pH, the amines are protonated and do not interact with the squaric 
ester residues. When the pH increases in a range of 4.5 to 8.5, the amine side chains 
become deprotonated and interact with squaric ester linkers. This interaction rigidifies 
the polymer creating and increasing relaxivity (Aime et al., 1999a). Also Hartman and 
colleagues synthetised ultrashort singe-walled carbon nanotube capsules that provided 
extremely high and pH-dependent relaxivity. These so-called gadonanotubes showed an 
increased relaxivity upon a decrease in pH from 7.4 to 7.0 (Hartman et al., 2008).   
These smart contrast agents have proven to be excellent MRI tools for very 
specific targets in vitro, but failed to show the same performance in vivo, due to the 
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absence of sensitivity and selectivity towards tissues of interest. Several attempts have 
been made to improve these setbacks, including an increase in the number of contrast 
agents attached to monoclonal antibodies (MAb). However, these solutions have failed.  
The new smart polymeric micelles loaded with Gd(III) complexes, besides 
exploring the characteristic features of cancer tissues (e.g. low extracelular pH and 
leaky vasculature) they accumulate and specifically image these lesions. Moreover, they 
can be bioconjugated with MAbs recognizing specifically cancer biomarkers, thus 
reinforcing their specificity for cancer tissue. 
 
4. CANCER MICROENVIRONMENT 
The cancer microenvironment has several characteristics that distinguish it from normal 
tissues. These features have been explored by smart and targeted nanoparticle-base CA 
to improve early cancer detection. The abnormal regulation of proliferation and 
apoptosis in cancer cells originates a pathological and disorganized increase in cell 
number and density. This results in a decreased access of tumor cells to the circulatory 
system (Gillies, Schornack, Secomb, & Raghunand, 1999). Consequently, there is a 
deficient supply of nutrients and oxygen and an insufficient washout of metabolic 
products (Bristow & Hil, 2008). In addition, the increase in aerobic glycolysis by cancer 
cells (Reshkin et al., 2000), creates a cancer microenvironment characterized by 
abnormal physiologic conditions such as hypoxic areas, low levels of serum nutrients, 
acidic extracellular pH (Penet, Glunde, Jacobs, Pathak, & Bhujwalla, 2008; Gillies et 
al., 2004), disorganized vasculature and inefficient lymphatic vessels (Rhyner et al., 
2008). 
In cancer tissues there is a reversed pH gradient across the cell membrane. 
Cancer cells normally have alkaline intracellular pH values (7.12–7.65 compared with 
6.99–7.20 in normal tissues) and acidic interstitial extracellular pH values (6.2–6.9 
compared with 7.3–7.4) (Gillies et al., 2002). This pH gradient seems to be present upon 
cancer cell transformation. The development and maintenance of this gradient is directly 
due to the ability of the cancer cells to secrete protons and acidify their extracellular 
environment, which will trigger mechanisms favoring tumor invasiveness and 
aggressiveness (Cardone, Casavola, & Reshkin, 2005). Indeed, the low extracellular pH 
of the tumor microenvironment has been shown to promote angiogenesis, accelerate the 
digestion and remodeling of the extracellular matrix by facilitating the action of acidic 
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proteases that are secreted by tumor cells, create genomic instability, and radiotherapy 
resistance (Orive, Reshkin, Harguindey, & Pedraz, 2003; Gatenby & Gillies, 2004).  
Angiogenesis is vital for the development of most solid and hematologic 
cancers. As mentioned above, it occurs in response to metabolic alterations of the tumor 
microenvironment (Winter et al., 2003; Penet et al., 2008). These changes cause a 
cascade of cellular events that stimulate the production of angiogenic factors and 
decrease the production of angiogenesis inhibitors (Elias & Dias, 2008). Angiogenic 
factors induce endothelial cells to proliferate, invade, and migrate towards cancer cells, 
establishing the typically fragile, tortuous, disorganized and leaky vascular structure of 
cancers (Folkman, 2007).  
Nanoparticles extravasate and accumulate preferentially at tumor interstitial 
spaces through the enhanced permeability and retention (EPR) effect. This effect is due 
to the increased permeability of tumor neovasculature and the dysfunctional lymphatic 
drainage system (Matsumura & Maeda, 1986; Rhyner et al., 2008). This nanoparticle 
accumulation through fenestrated capillaries into the tumor interstitial space is 
designated as passive targeting (Kairemo et al., 2008)., After performing experiments 
with liposomes of several sizes, Yuan and colleagues proposed that the limit 
nanoparticle size for extravasation into tumors is 400 nm (Yuan et al., 1995). Passive 
targeting has been extensively explored to obtain accumulation of nanoparticles in 
tumor lesions. This approach has however several limitations, such as the heterogeneous 
permeability of the vessel walls to macromolecules throughout the tumors. Moreover, 
some tumors do not show the EPR effect, and this kind of targeting is quite random as 
well as difficult to be controlled (Yuan et al., 1994; Daldrup et al., 1998; Peer et al., 
2007). To overcome these hurdles, active targeting has been increasingly used. This is 
achieved by conjugating nanoparticles with molecules that bind overexpressed antigens 
or receptors on target cancer cells (Torchilin, 2007). 
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5. MUC1 PROTEIN 
The mucin 1 (MUC1) protein was chosen as a cancer cell receptor for this new targeted 
MRI nanoparticle-based CA due to its demonstrated great potential for early detection 
and staging of cancers (Medarova, 2009).  
The mucin family comprises proteins with tandem repeat structures rich in 
prolines, threonines and serines. The human mucin family is composed of many 
members designated from MUC1 to MUC21, and have been subclassified into secreted 
and transmembrane forms (Singh & Bandyopadhyay, 2007). 
MUC1 (PEM, episialin, EMA, CD227, DF3) is a high-molecular-weight type I 
membrane glycoprotein with around 150-300 kDa. This glycoprotein is translated as a 
single polypeptide and is cleaved in the endoplasmic reticulum to form amino- and 
carboxy-terminal subunits (Levitin et al., 2005). The two MUC1 subunits form a stable 
non-covalent complex that is heavily O-glycosylated during transit through the Golgi 
complex. Then, this heterodimeric complex is anchored to the surface of the cell. The 
MUC1 N-terminal subunit is released from the cell surface into the mucous gel, leaving 
behind the MUC1 C-terminal portion. This domain functions as a receptor to detect the 
presence of inflammation and other forms of stress, and thus send signals to the interior 
of the cell (Kufe, 2009). The N-terminal subunit consist of up to 100 repeats of nearly 
identical O-glycosylated highly conserved variable number tandem repeat (VNTR) units 
of 20 amino acids (PDTRPAPGSTAPPAHGVTSA), flanked at both sites by a non-
repeat region (Murray et al., 2001). Structurally, the C-terminal subunit includes a small 
extracellular domain, a transmembrane domain plus a cytoplasmic tail (CT). This 
subunit is 69 amino acid-long and has several tyrosine, serine, and threonine 
phosphorylation sites that when phosphorylated can bind to several proteins implicated 
in signaling pathways linked to transformation and cancer progression (Kufe, 2008). 
Normally, MUC1 is localized on the apical borders of normal secretory 
epithelial cells. In response to stress, in order to protect the epithelial cell layer, this 
protein loses its polarity, being transiently repositioned over the entire cell membrane. 
The loss of polarity allows MUC1 to interact with cell surface molecules situated at the 
basolateral membrane and thus trigger cell proliferation and survival (Vermeer et al., 
2003). MUC1 is upregulated in response to infection by pathogenic bacteria (McAuley 
et al., 2007). This is a defense mechanism, but prolonged stimulation of MUC1 in 
chronic inflammation can lead to deregulated cell growth and survival, as well as the 
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development of cancer (Kufe, 2009). MUC1 is also overexpressed during lactation 
(Rahbarizadeh, Rasaee, Moghadam, Allameh, & Sadroddiny, 2004), and when 
overexpressed in MMTV-MUC1 transgenic mice delays mammary postlactation 
involution, probably due to reduced apoptosis. Importanly, MUC1 overexpression in 
these transgenic mice promoted in vivo transformation of the mammary gland 
(Schroeder et al., 2004). 
 
5.1. A TARGET MOLECULE FOR CANCER IMAGING 
A valuable cancer biomarker is recurrently overexpressed in tumors and demonstrates 
negligible expression in normal tissues. To be useful, these tumor antigens should allow 
cancer detection in asymptomatic patients, thus improving the accuracy of current 
screening techniques (Brooks, 2009). MUC1 has long been recognized to gather several 
of these requisites.  
This protein has been implicated in malignant cell transformation as well as 
cancer progression through stimulation of cell proliferation and apoptosis suppression 
(Bafna, Kaur, & Batra, 2010). Thus the MUC1 CT has been studied to understand its 
role as an oncoprotein (Huang et al., 2005). MUC1 has also been shown to promote 
metastasis, and has been associated with biologically aggressive tumors and a worse 
prognosis (Zhao et al., 2009). Another evidence supporting the notion that MUC1 is 
involved in malignant disease, is its high level of expression over the entire cell surface 
and intracellularly in almost all human epithelial cell adenocarcinomas (Figure 11). 
Some examples are breast, stomach, colorectal, lung, prostate, ovarian, pancreatic, and 
bladder cancers  (Masri & Gendler, 2005; Cheng, Su, Wang, & Yu, 2009; Murray et al., 
2001). Certain hematological malignancies (e.g. multiple myeloma cells, lymphomas 
and myeloid leukemias) also present MUC1 overexpression (Singh & Bandyopadhyay, 
2007). 
Figure 11 - MUC1 expression on normal and cancer cells. MUC1 is 
normally localized at the apical border of normal epithelial cells. 
However in cancer cells it is ubiquitously expressed all over the cell 
surface. Adapted from (Gendler, 2001). 
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In addition, the glycosylation pattern of the MUC1 N-terminal tandem repeats is 
altered in human carcinomas. MUC1 is hypoglycosylated and contains truncated or 
incomplete oligosaccharide side chains (Xiong, Natarajan, Shi, Denardo, & Denardo, 
2006) (Figure 12). The underglycosylated MUC1 tumor-specific antigen has been 
pinpointed as one of the early hallmarks of tumorigenesis in breast, pancreatic and 
ovarian cancer (Medarova, Pham, Kim, Dai, & Moore, 2006; Mommers et al., 1999).  
 
Regarding specifically breast cancer, it is known that approximately 90% of 
these cancers are positive for MUC1 (Mahanta, Fessler, Park, & Bamdad, 2008).  
In many cases, large amounts of MUC1 N-terminal subunit are detected in the 
blood of breast cancer patients, as a consequence of cleavage and shedding of this 
domain from the cell surface (Mahanta et al., 2008). This finding makes serum assays 
for MUC1 a potentially useful method for breast cancer detection (Ferreira et al., 2008). 
There are commercially available serum tumor marker assays using anti-MUC1 
antibodies to measure concentration levels of circulating MUC1 N-terminal subunit, 
such as CA 15-3, Truquant-Br, CASA, CA549, MCA and CA 27.29 (Bon et al., 1997; 
Gendler, 2001). Determination of the level of this antigen in the blood has been 
exploited as a measure of tumor burden. In addition, the MUC1 changing levels reflect 
the response to therapy and allow detection of early disease recurrence (Kufe, 2009). 
Figure 12 - MUC1 glycosylation pattern at a cancer cell 
surface membrane. MUC1 is heavily glycosylated on 
normal cells, whereas in cancer cells it is underglycosylated. 
The insert shows a MUC1 single tandem repeat unit with O-
linked hypoglycosylated side chains. Adapted from (Berge et 
al., 2001) 
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MUC1 is atypically overexpressed in several cancers. Therefore this protein 
became a promising target for the development of specific antibodies, vaccines and 
therapeutic inhibitors. Different types of murine anti-MUC1 MAbs were shown to 
recognize the MUC1 tumor marker and have recently underwent clinical trials (Kufe, 
2009).  
The MAb C595 was used as a specific targeting vector for ovarian cancer cells. 
C595 was labeled with Bismuth-213 and proved to effectively target and kill ovarian 
cancer cells in vitro and in in vivo cancer mouse models (Song et al., 2008). In a small 
clinical study, Hughes and colleagues used Indium-111
 
-labelled C595 MAb to detect 
invasive bladder cancer and metastases. This imaging approach demonstrated potential 
to improve clinical staging and detection of lesions not detected by conventional 
modalities (Hughes et al., 2001). Saloutia and co-workers labelled the MAb PR81 with 
Technetium-99m. The visualization of breast tumors in animal models with high 
sensitivity proved the potential of this new radiopharmaceutical to be used for 
radioimmunoscintigraphy of human breast cancer (Saloutia, Rajabia, Babaeib, & 
Rasaeec, 2008). 
For imaging and therapy by hyperthermia of MUC1-expressing tumors, another 
research group conjugated commercial PEG-coated dextran-magnetic nanoparticles 
with isotope and antibody fragments against MUC1 (Natarajan, Xiong, Gruettner, 
DeNardo, & DeNardo, 2008). Using short specific peptide sequences derived from a 
MAb and combining two imaging modalities, another group successfully detected 
tumors that overexpressed the tumor-specific underglycosylated MUC1 antigen (Moore, 
Medarova, Potthast, & Dai, 2004). MUC1 was also detected by quantum-dot 
fluorescence using an aptamer-based approach. This work allowed detection of MUC1 
protein and quantification of the amount of protein in a peptide sample (Cheng et al., 
2009). 
Two vaccines against MUC1 are in different phases of clinical trials for non-
small cell lung carcinoma. The L-BLP25 liposome vaccine (stimuvax) was developed to 
stimulate the immune response against MUC1 tandem repeats, while the TG4010 
(Transgene) is a modified vaccine virus expressing MUC1 and Il-2. Patients received 
the TG4010 vaccine with chemotherapy (Kufe, 2009). Despite these efforts, there are 
presently no validated agents applied in the clinic that are specific and efficient enough 
to target MUC1 (Kufe, 2009). 
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6. BREAST CANCER 
The MUC1 protein is aberrantly expressed in the majority of breast cancer cases, even 
less aggressive early stage cancers. Recognition of tumor-specific expression of this 
protein by MRI with the new targeted pH-sensitive micelles could be very useful for 
early breast cancer detection, staging and prognosis (Medarova, 2009). 
Breast cancer is the most frequent form of cancer in women and the commonest 
cause of death among women aged 40–50 years (McPherson, Steel, & Dixon, 2000). 
For a woman of average risk, it is estimated that the lifetime incidence of breast cancer 
is one in eight (Brooks, 2009). Breast cancer is particularly difficult to treat when it 
metastasizes and becomes resistant to antiestrogen therapies (Bernard-Marty, Cardoso, 
& Piccart, 2004). Therefore, early breast cancer detection has been the major factor in 
the reduction of mortality and reduction of cancer management costs (Fass, 2008). 
 
6.1. TUMORIGENESIS 
Breast cancer carcinogenesis is a multistep process, which takes different pathways, 
with mutations occurring in different genes and in distinct mammary cell types. This 
biological diversity is manifest in the existence of distinct clinically important tumor 
histological subtypes (Barros & Barros, 2009).  
The initiation of tumorigenesis is caused by genetic alterations, which can be 
chromosomal translocations, deletions, point mutations or amplifications, and result in 
the loss of function of tumor suppressor genes (more frequent) or in the activation of 
proto-oncogenes (Gasco, Shami, & Crook, 2002). Relatively to its initiation process, 
breast cancers could be classified as sporadic or nonhereditary, which represent 90 to 
95% of the cases and as hereditary or familiar, contemplating 5 to 10% of breast tumors 
(Samphao et al., 2009). Sporadic breast cancers occur in older women as a consequence 
of several accumulated somatic gene mutations. Hereditary or familial breast tumors are 
characterized by young age onset and bilaterality. This is due to a germline mutation in 
a single allele of high penetrance cancer susceptibility genes, such as BRCA1, BRCA2, 
TP53, CDH1, CHEK2 or PTEN. Inactivation of the second allele of these tumor 
suppressor genes (loss of heterozigosity) is an early event in this oncogenic pathway 
(Knudson’s ―two-hit‖ model) (Knudson, 2001) . 
In the phase of promotion, once the initial changes have occurred, the 
genetically modified cells stimulated by promoting factors expand and cause tumors 
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(Barros & Barros, 2009). The most important tumor promoters in mammary 
carcinogenesis are steroid hormones, whose influence on the breast depends on the 
stage of maturation and differentiation of duct-lobular unit. Estrogens are the main 
drivers in stimulating mammary cell proliferation, although its action is potentiated by 
the presence of progesterone (Osborne & Schiff, 2005).  
Progression is associated with a breakdown of cadherin-mediated cell adhesion 
and consequent local invasion by tumor cells. Neoplastic cells, present in an initial 
tumor, can cross the subepithelial basement membrane and reach the underlying 
interstitial stroma. This allows malignant cells to access the lymphatic and/or blood 
vessels and eventually cause metastasis. These events mark the transition of in situ to 
infiltrating breast cancer. Neoangiogenesis is essential for tumor dissemination and 
metastasis; however the lymphatic spread of breast cancer is the preferred route 
(Schneider & Miller, 2005). The newly formed lymphatic vessels are larger than blood 
capillaries and have an incomplete basement membrane, which facilitates dissemination 
to the lymph nodes. Once in lymphatic organs, cancer cells can reach others organs. 
When breast cancer spreads, cancer cells most often seed in the bones (60%), lungs 
(20%), liver (15%) but rarely in brain, ovary and skin (Engel et al., 2003). 
 
6.2. CLASSIFICATION 
Breast cancer is biologically a heterogeneous disease. It encompasses several important 
tumor subtypes, each one with a distinct origin, genetic composition; evolution history 
and affected tissues (epithelial, mesenchymal and myoepithelial) (Burstein, 2005).  
 
6.2.1. HISTOPATHOLOGICAL SUBTYPES 
The histopathological classification of breast cancers is important for tumor diagnosis 
and consequently to determine patient prognosis. Each mammary gland is composed of 
multiple lobules connected to ducts and surrounding tissue (stroma), which includes 
blood and lymphatic vessels, nerves and adipose tissue. Breast cancers may originate 
from any of the mentioned tissues (Carvalho, 2009).  
Ductal carcinoma in situ (DCIS) or non-infiltrative breast carcinoma is 
characterized by malignant epithelial cell proliferation confined to the mammary ducts, 
without crossover of the basement membrane (Pinder & Ellis, 2003).  
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Lobular intra-epithelial Neoplasia (LIN) is an uncommon disease and is 
characterized by noninvasive proliferative lobular lesions. LIN has been associated with 
an increased risk for developing invasive bilateral breast cancer (Hwang, Barke, 
Mendelson, & Susnik, 2008).  
Concerning invasive breast carcinomas, the latest classification of the World 
Health Organization Classification of tumors (2003) distinguishes at least 30 invasive 
tumor types (Meijnen, Peterse, Antonini, Rutgers, & van de Vijver, 2008). The invasive 
ductal carcinoma (IDC) or infiltrating ductal carcinoma is the most common type of 
breast cancer, comprising 70-80% of all cases. It is frequently associated with DCIS. 
IDC commonly spread to the regional lymph nodes (Hawthorn, Luce, Stein, & 
Rothschild, 2010). The invasive lobular carcinoma is relatively uncommon, comprising 
only 8-15% of breast tumors. There are other histological types with distinct biological 
behavior (Carvalho, 2009). 
 
6.2.2. GENETIC ALTERATIONS 
The expression status of ER and progesterone receptors (PR) and the presence of HER2 
gene (HER2/neu) amplification is important for breast cancer diagnosis. Gene 
expression profiling of several breast cancers has demonstrated the existence of five 
major molecular subtypes, including basal-like, luminal A, luminal B, HER2
+
/ER
–
 and 
normal breast–like (Perou et al., 2000). Importantly, these molecular divergences were 
shown to be associated with different clinical behavior and response to treatment (Sorlie 
et al., 2001). 
The luminal types (A and B) are defined by high expression of ER and related 
genes (Morris & Carey, 2007). Luminal A breast cancers are associated with a better 
prognosis because patients respond better to hormonal therapy. In contrast, luminal B 
types are more resistant to this therapy (Rakha, Reis-Filho, & Ellis, 2010). The normal 
breast-like subtype expresses genes also expressed in adipose tissue and non-epithelial 
cell types (Sorlie et al., 2001). The HER2-positive subtype is characterized by high 
specific expression of HER2 (Perou et al., 2000). This protein receptor is important for 
cell growth regulation. When its gene is amplified, there is an overproduction of HER2 
and activation of its downstream signaling pathways, thus leading to increased cell 
proliferation and concomitant development of aggressive tumors associated with poor 
patient prognosis. The basal-like subtype is characterized by low expression of the ER, 
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PR and HER2 genes in microarray analysis. Indeed, using clinical bioassays for breast 
cancer protein biomarker (ER, PR and HER2) detection, this histological subtype is 
frequently negative for ER, PR and HER2, so being often designated ―triple-negative‖ 
(Dawson, Provenzano, & Caldas, 2009; Yezhelyev et al., 2006). There are limited 
effective options to treat patients with basal-like breast carcinoma, who have therefore 
poor prognosis (Draheim et al., 2010).  
 
6.3. BREAST CANCER SCREENING AND DIAGNOSIS 
Annual screening mammograms of asymptomatic women have been shown to reduce 
breast cancer mortality (Smart, Hendrick, Rutledge, & Smith, 1995). However, breast 
screening using MRI is more efficient for women with high risk for breast cancer 
development due to family history (Turnbulla, 2009). MRI showed a great potential in 
improving the detection of early stage breast cancers with small sizes in young, high-
risk women without symptoms at clinical examination (Samphao et al., 2009). 
Cancer cells often express characteristic antigens since their early onset. Using 
target probes for these molecular cancer markers, one can potentially improve the early 
diagnosis of cancer and thus treat it more efficiently (Brooks, 2009). Several biomarkers 
have been under clinical investigation for immunotherapy, targeted imaging of cancer, 
chemotherapy, and radiation therapy. Some have appeared to be valuable, though few 
have reached clinical applicability (Rakha et al., 2010).  
Current histopathologic evaluation of breast cancer determines the ER/PR status, 
because their expression usually correlates with an enhanced response to chemo- or 
hormone therapy and consequently a better prognosis. The overexpression of HER2 is 
also important, because it enables the use of the trastuzumab (Herceptin) MAb 
(Yezhelyev et al., 2006). However, HER2/neu is only overexpressed in 25–30% of 
breast cancer patients (Sood, 2009). Other antigens have been used for targeted therapy 
and imaging of breast cancer, such as the carcinoembyonic antigen (Goldenberg et al., 
2000), the tumor-associated antigen L6, the Thomsen-Friedenreich disaccharide 
(Goldenberg, 2002), the tumor-associated glycoprotein 72 (Macey et al., 1997) and 
EGFR (Ke et al., 2003). 
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7. AIMS OF THE PROJECT 
The final aim of this research project is to develop pH-sensitive nanoparticles able to 
target specifically to cancer tissues a contrast agent for MRI. To verify the suitability of 
the newly designed pH-sensitive contrast agent for MRI molecular imaging, I had the 
following main goals: 
1) Assess the in vitro cytotoxicity of free and micelle-encapsulated Gd(III) 
complexes; 
2) Verify by MRI whether pH-sensitive micelles disassemble and release their 
content; 
3) Confirm MUC1 gene and protein expression in breast cancer cell lines to be 
used as targets; 
4) Verify whether micelle bioconjugation with a MUC1 antibody increased 
their targeting ability towards MUC1-expressing breast cancer cells; 
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1. BIOCONJUGATION AND POLYMERIC MICELLE PREPARATION 
The preparation of polymeric micelles, their bioconjugation, and encapsulation of 
Gd(III) complexes or fluorophore was performed based on a previously reported 
procedure (Mouffouk et al., 2008). 
 
Preparation of Gd(III) complex solution 
Hydrophobic Gd(III) complexes (tetra-aquodichloro (4,4'-ditBu-2,2'-bipyridine) 
gadolinium (III) chloride) were synthesized by Dr. André Lopes. The contrast agent was 
synthesized based on a well-described method to produce hydrophobic Gd(III) 
complexes with ligands such as bipyridine (Bechara et al., 2009). The resultant Gd(III) 
complex had a molar mass of 604.067 g.mol
-1
. To obtain a 50 mM stock solution, 5.1 
mg of Gd(III)
 complex were dissolved in 169 μL of ethanol (96%)(AGA). The solution 
was kept at -20ºC. 
 
Preparation of Gd(III) complex-loaded polymeric micelles 
Loaded polymeric micelles with Gd(III) complexes were obtained as follows: 30 mg of 
poly(ethylene glycol-b-trimethylsilyl methycrylate) and 0.5 mg of Gd(III) complexes 
were dissolved in 0.3 mL of N,N-Dimethylformamide (DMF) (BDH Prolabo). The 
mixture was stirred for 3 hours at room temperature. Subsequently, 0.7 mL of pure 
Milli-Q water was added at a rate of one drop every 10 s to induce micellization. The 
resulting micelle solution was then placed in a dialysis cassette (Thermo Scientific) with 
a 10 kDa cut-off and dialyzed against Milli-Q water for 1 day at room temperature. 
Then, 0.5 mL from the solution in the dialysis cassette were collected and the remaining 
was dialyzed for 3 days at room temperature. The Milli-Q water was replaced twice a 
day. 
 
Preparation of fluorophore-loaded polymeric micelles  
Polymeric micelles loaded with the 1-methylpyrene fluorophore were prepared by 
adding 30 mg of poly(ethylene glycol-b-trimethylsilyl methycrylate) to 0.5 mg of 1-
methylpyrene (Fluka) and dissolved in 0.4 mL DMF. The mixture was stirred for 3 
hours at room temperature. Subsequently, 1 ml of Milli-Q water was added at a rate of 
one drop every 10 s to induce micellization. The resulting micelle solution was then 
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placed in a dialysis cassette with a 10 kDa cut-off and dialyzed against Milli-Q water 
for 2 days at room temperature. The Milli-Q water was replaced twice a day. 
 
Bioconjugation of polyethylene glycol with anti-MUC1  
Bioconjugation of PEG with mouse MAbs against the human MUC1 protein (C595; 
Santa Cruz Biotechnology) was performed as follows: 3 mg of methoxypolyethylene 
glycol N-hydroxysuccinimide ester (Sigma-Aldrich) was added to a solution containing 
3 µg of C595 (30 µL) in 0.1 M bicarbonate buffer (500 µL, pH=8.3). The mixture was 
gently stirred for 5 days in slow tilt rotation at 4
°
C.  
 
Preparation of fluorophore-loaded bioconjugated micelles 
Loaded bioconjugated micelles were prepared by adding 30 mg of poly(ethylene glycol-
b-trimethylsilyl methycrylate) with 0.5 mg of 1-methylpyrene and dissolved in 0.4 mL 
of DMF. The mixture was stirred for 3 hours at room temperature. Subsequently, 
0.5 mL PEG-Anti-MUC1 aqueous solution was added at a rate of one drop every 10 s 
and, immediately after, 0.5 mL of cold Milli-Q water was added at the same rate to 
induce micellization. The resulting micelle solution was then placed in a dialysis 
cassette with a 10 kDa cut-off and dialyzed against cold Milli-Q water for 1 day at 4ºC. The 
Milli-Q water was replaced once. 
 
2. DETECTION OF NANOPARTICLES-BASED CONTRAST AGENT “ON” 
AND “OFF” STATES 
To image Gd(III) complexes released from Gd(III) complex-loaded micelles a 1.5 Tesla 
(T) MRI (Signa 1.5T SYS#GEMSOW, GE Healthcare) was used. The same volume of 
Gd(III) complex-loaded micelles in Milli-Q water was dispensed in two microfuge 
tubes. Next, hydrochloric acid (HCL) (37%) (Merck) was added to one of these 
microfuge tubes. Both tubes were positioned above a MRI phantom for calibration. MR 
images were subsequently acquired with a Fast Spoiled Gradient Echo sequence 
(TR/TE= 150/4.2 milliseconds; Flip angle, 90º; slice thickness, 4 mm; field of view, 
24x18 cm; matrix, 256x256). 
The Gd(III) complex-loaded micelles were also tested in mice. One mouse was 
intramuscularly injected (50 μL) in one hind leg with 0.1 M Acetate buffer (pH=4). 
Subsequently, the mouse was intramuscularly injected (50 μL) with the pH-sensitive 
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polymeric micelles loaded with Gd(III) complexes in both hind legs. The mouse was 
then positioned inside a MRI head coil and MR images were subsequently acquired. 
 
3. MEASUREMENT OF Gd(III) COMPLEXES AND FLUOROPHORE 
CONCENTRATIONS 
1-methylpyrene calibration curve 
From a stock solution of 2.17x10
-5
 M of 1-methylpyrene in tetrahydrofuran (THF, 
High-performance liquid chromatography (HPCL) grade, Ridel-de-Haën), five 
standards of concentrations 1.63x10
-5
, 1.09x10
-5
, 8.68x10
-6
, 5.43x10
-6
 and 1.09x10
-6
 M 
were prepared. The standard absorbances were measured (Varian Cary 50 UV-Vis 
spectrophotometer) at 344 nm and the calibration curve obtained by fitting the 
absorbance with concentration data. A value of 3.01x10
4
 dm
3
.mol
-1
.cm
-1
 for the molar 
absorption coefficient was found. Given the calibration curve, the absorbance from two 
different samples, one of bioconjugated 1-methylpyrene-loaded micelles and other from 
non-target micelles was measured. For measurements, THF was added to 30 μL of a 
sample with unknown concentration until reaching 3 mL in the cuvette, obtaining a 100-
fold dilution. 
 
Gd(III) complex calibration curve 
A stock solution of Gd(III) complex in ethanol (96%, AGA) 6.62x10
-5
 M was diluted to 
obtain standards with the following concentrations: 3.31x10
-5
, 1.66x10
-5
, 3.31x10
-6
, 
1.66x10
-6
 and 3.31x10
-7
 M, whose absorbances were recorded at 282 nm. The molar 
absorption coefficient was 1,26x10
4
 dm
3
.mol
-1
.cm
-1
. 
 
4. CELL LINES AND CULTURE CONDITIONS 
Cell Lines 
The Jurkat (human T-cell leukemia), MCF-7 and MDA-MB-468 (human breast 
adenocarcinoma) cells lines were kindly supplied by Dr. João Barata (IMM, Lisbon), 
Dr. Raquel Seruca and Dr. Joana Paredes (IPATIMUP, Porto) respectively. The S17 
(mouse bone marrow stromal) cell line was provided by Dr. Leonor Parreira (IMM, 
Lisbon). The HeLa (human cervical cancer) and 293T (human Embryonic Kidney) cell 
lines were provided by Dr. Guilherme Ferreira (IBB/CBME, Faro), the DND41 (human 
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T-cell leukemia) cell line by Dr. Hind Medyouf (Terry Fox Laboratory, Vancouver) and 
the human retinal pigment epithelium cell lines, ARPE19 and D407, by Dr. Gabriela 
Silva (IBB/CBME, Faro). 
 
Cell Culture 
The MCF-7, MDA-MB-468, HeLa, 293T; ARPE19; D407 and S17 adherent cell lines 
were maintained in DMEM medium (LONZA) supplemented with 10% fetal bovine 
serum (FBS) (PAA), 200 mM glutamine, 10000 units/mL penicillin and 10000 μg/mL 
streptomycin (LONZA). All cell culture incubations were performed at 37ºC under 
humidified atmosphere of 5% CO2, unless stated otherwise. The Jurkat and DND41 
suspension cell lines were maintained in RPMI 1640 medium (LONZA) supplemented 
as above. Cells were thawed at 37ºC and pipetted into 10 mL of pre-warmed medium. 
Cells were centrifuged at 300 g for 5 minutes to remove dimethylsulfoxide (DMSO) 
(Merck). Then, the supernatant was discarded and the pellet resuspended in 2 mL of 
fresh medium. The cells were placed into T25 flasks (Nunc) and 8 mL of medium was 
added for a final volume of 10 mL. The medium was changed every 2 days. To count 
adherent cells, these were first detached by removing the medium, followed by washing 
with phosphate-buffered saline (PBS) (LONZA) and addition of 1 mL of 0.25% trypsin 
(LONZA) per 59 cm
2
. Then, the cells were allowed to detach for 1 to 5 minutes 
(depending on cell line) at 37ºC, before resuspension in DMEM medium. To dissociate 
cell aggregates, both suspension and adherent cells were gently pipetted. Then, 30 μL of 
cell suspension were placed into a microfuge tube together with 30 μL of 0.4% Trypan 
Blue (Sigma-Aldrich) and mixed. The hemocytometer Neubauer chamber (Hausser 
Scientific) was filled with the cell suspension and uncolored viable cells were counted 
on an inverted light microscope (Leica DM IL). The cells were counted in four 1 mm
2
 
squares. The equation to calculate the cell number per cubic millimeter is the following: 
number of cells counted per square millimeterdilution used10. 
 
5. IN VITRO CYTOTOXICITY TESTS 
Cell counting to assess Gd(III) complex cytotoxicity 
Jurkat cells were seeded on 6-well culture plates (BD Falcon) (2 mL in each well with a 
concentration of 2x10
5
 cells/mL). Different concentrations (1, 5, 10 and 50 μM) of 
Gd(III) complex solution, diluted in 50 μl RPMI1640, were added to the cells. Each test 
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was performed in duplicate. Untreated cells served as controls. Cells were incubated for 
3 days, and each day cells were collected for counting. 
 
MTT assay to assess cytotoxic Gd(III) complex concentrations  
Two different cell lines were used to assess Gd(III) cytotoxicity: Jurkat, and MCF-7. 
Jurkat cells were seeded on two 96-well culture plates (BD Falcon) (50 μl in each well 
with a concentration of 4x10
5
 cells/mL). Different concentrations (5, 10, 15 and 20 μM) 
of Gd(III) complex solution, diluted in 50 μl of RPMI1640, were used. Each test was 
repeated eight times. As a negative control, cells were treated with ethanol (96%) (the 
same amount of ethanol given to cells treated with the highest concentration of Gd(III) 
complex). Incubation was carried out for 3 days. In this experiment the toxicity of 
Gd(III) complex was evaluated by the 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl 
tetrazolium bromide (MTT) assay. This assay is based on the accumulation of formazan 
crystals inside living cells after their exposure to MTT. The reduction of MTT is 
attributed mainly to mitochondrial enzymes and electron carriers, so it only occurs in 
metabolically active cells. Destruction of cell membranes by the addition of an organic 
solvent resulted in the release and solubilization of the crystals. The amount of crystals 
can be determined spectrophotometrically and thus estimates the number of 
mitochondria and hence the number of living cells in the sample (Freimoser, Jakob, 
Aebi, & Tuor, 1999). At the end of each incubation time 10 μl of 5 mg/mL MTT 
solution (AppliChem) were added to each well followed by further incubation for 4h. 
Then, 100 μl of 0.04 N HCL in isopropanol (BDH Prolabo) were added to the wells and 
formazan crystals were allowed to solubilize for 1 hour at room temperature. The 
formazan concentration was quantified using a spectrophotometer (Tecan Infinite M200 
monochromator-based multi-function microplate reader) by measuring the absorbance 
at 570 nm and 630 nm. The final optical density (OD) obtained from formazan 
formation was calculated with the following formula: OD=L(570nm)-L(630nm). The toxicity 
was assessed by calculating the % of cell survival in relation to the control untreated 
group. The procedure described above was repeated for the MCF-7 cell line, after being 
seeded at 5103 cells per each well and allowed to attach for 24h.  
 
MTT assay to assess Gd(III) complex-loaded polymeric micelle cytoxicity 
To assess Gd(III) complex-loaded polymeric micelle cytoxicity and to compare it with 
the toxicity from free Gd(III) complex, Jurkat cells were seeded on a 96-well culture 
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plate (50 μl in each well with a concentration of 4x105 cells/mL). Different 
concentrations of Gd(III) complex and Gd(III) complex-loaded polymeric micelles 
dialyzed for 24 hours or for 96 hours (at concentrations of 10 μM or 50 μM) diluted in 
50 μl of RPMI-1640 were added to the cells. Each test was performed in quadruplicate. 
Untreated cells, or cells treated with solvent (ethanol or Milli-Q water) served as 
controls. Cells were incubated for 72h. The cytotoxicity of Gd(III) complex and Gd(III) 
complex-loaded polymeric micelles was evaluated by the MTT assay following the 
procedure mentioned above. The results were analyzed by Student’s t-test with P < 0.05 
significance, using GraphPad Prism software. 
 
6. ANALYSIS OF MUC1 EXPRESSION 
6.1. SDS-PAGE AND WESTERN BLOTTING 
Cell lysis in RIPA buffer 
DND41 and trypsinized MCF-7 cell lines were washed twice in 1 mL of cold PBS. The 
supernatant was discarded and PBS removed without disturbing the cell pellet. Protein 
extracts were obtained by lysing cells in ice-cold RIPA buffer [10 mM Tris, pH 7.4; 150 
mM NaCl; 1 mM EDTA; 1% Triton (100x); 0.5% Na deoxycholate; 0.1% SDS] with 
freshly added protease inhibitors (10 μg/mL aprotinin; 10 μg/mL leupeptin and 1 mM 
PMSF). 100 μL of RIPA buffer were added for each 10 million cells. After 
homogenization, the tubes were incubated on ice for 10 minutes. The cell debris was 
removed by centrifugation at 14000 rpm for 10 min and the cleared cell lysate 
transferred to a new microfuge tube. Samples were stored at -80ºC. For electrophoresis, 
60 μL of each lysate were mixed with 60 μL of 2SDS sample buffer (62.5 mM Tris, 
pH 6.8; 20% glycerol; 2% SDS; 5% β-mercaptoethanol; bromophenol blue). 
Subsequently the proteins were denaturated at 95ºC for 4 minutes.  
 
SDS-PAGE  
An 8% separating polyacrylamide gel was prepared using 30% 
acrylamide/bisacrylamide (37.5:1) (ProtoGel), 1M Tris (pH 8.8); 10% SDS, 10% 
ammonium persulphate (Applichem), N,N,N'N'-tetramethylethylenediamine (TEMED) 
Electran (BDH), and deionized water. A 4.5% stacking gel was prepared with the same 
reagents with exception of buffer, which was 5.5 M Tris, pH 6.8. The polymerized gels 
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were prepared on a mini-Protean (Bio-Rad) apparatus, following the manufacturer’s 
instructions. Tris-glycine electrophoresis buffer (25mM Tris, pH 8.3; 192 mM glycine; 
0.1% SDS) was added until gel submersion. Equal amounts (20 μL) of protein from 
MCF-7 and DND 41 cell lines were loaded onto the gel; and 5 μL of pre-stained high 
molecular weight protein markers (Precision Plus Protein Standards, Bio-Rad) were 
used as molecular weight standards. Gels were ran at 200 V constant voltage for 
approximately 45 minutes. 
 
Western Blotting  
Migrated proteins were electroblotted onto a 0.2 μm nitrocellulose membrane 
(Schleicher & Schuell). To this end, the gel was sandwiched between a pre-wet 
nitrocellulose membrane, six pieces of filter paper (Whatman 3MM) and fiber pads. The 
cassette was placed in the modular electrode assembly inside the buffer tank and filled 
with cooled transfer buffer (25mM Tris, 192mM glycine and 20% methanol). 
Electroblotting was carried out for 1 hour at 100 V constant voltage. Membrane 
blocking for 30 minutes and all antibody incubations were done at room temperature 
with 5% non-fat dried milk dissolved in 10 mL of PBS/0.1% Tween 20 (BDH Prolabo) 
(PBST). For protein detection, membranes were incubated sequentially with C595 
MUC1 monoclonal antibody (diluted 1/500) for 1 hour and horseradish peroxidase 
(HRP)-conjugated goat anti-mouse (AbD SEROTEC), (diluted 1/1000) during 45 
minutes. Excess antibodies were washed out 3 times during 10 minutes with PBST. All 
antibody incubations and washes were performed at room temperature with slow tilt 
oscillation. HRP detection was performed using the chemiluminescent detection kit, 
SuperSignal West Pico Chemiluminescent Substrate (Pierce), following the 
manufacturer’s instructions. Chemiluminescence was revealed by exposing the 
nitrocellulose membrane to a radiographic film (Amersham Hyperfilm - GE healthcare 
Life Sciences). For antibody dehybridization, the nitrocellulose membrane was 
incubated during 30 minutes at room temperature with a solution of 100 mL of distilled 
water with 570 μL of 100% acetic acid, and submitted to 3 washes of 10 minutes with 
PBST. Then, it was incubated with α-tubulin monoclonal antibody (Sigma-Aldrich) 
(diluted 1/10000) for 1 hour. Signal detection was done as described above for MUC1 
antibody.  
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6.2. RT-PCR 
RNA Extraction  
Total RNA was extracted from MDA-MB-468, MCF-7, Hela, 293T, ARPE19 and D407 
cell lines as described below. The cells were cultured on 60 mm culture dishes and 
allowed to grow until sub-confluence. The medium was removed, culture dishes were 
washed with PBS and 1 mL of TRIZOL reagent (Invitrogen) was added directly to the 
cells. The cells were lyzed by repeated pipetting, and allowed to incubate at room 
temperature for 5 minutes. Subsequently, 0.2 mL of chloroform (BDH Prolabo) was 
added to the cells, mixed and allowed to incubate at room temperature for 10 minutes. 
Next, the tubes were centrifuged at 12000 g, for 10 minutes at 4ºC, and the aqueous 
phase transferred to a new clean 2 mL microfuge tube. To precipitate RNA, 0.5 mL of 
isopropanol (BDH Prolabo) was added to the aqueous phase and mixed. The samples 
were incubated at room temperature for 10 minutes. Then, the samples were centrifuged 
at 12000 g, for 10 minutes at 4ºC. The supernatant was discarded, and 1 mL of 75% 
RNase-free ethanol was added, mixed by vortexing and centrifuged at 7500 g for 5 
minutes at 4ºC. The supernatant was discarded and the samples were allowed to dry by 
vacuum for 10-15 minutes. Depending on the size of the obtained visible RNA pellet, 
20 to 50 μL of RNase-free water was added to dissolve the pellet, and incubated for 10 
minutes at 60ºC. The concentration and purity of isolated RNA was measured by 
NanoDrop 2000c Spectrophotometer (Thermo Scientific), and its quality assessed by 
1% agarose (LONZA) gel migration in TAE buffer (40 mM Tris-Acetate; 0.5 mM 
EDTA, pH 8.5). The RNA samples were stored at -80ºC. 
 
DNase treatment  
Treatment of RNA with DNase I, RNase-free (Fermentas, #EN0521) was performed to 
obtain DNA-free RNA for RT-PCR. Thus, 1 μg of RNA in 9 μL of DEPC-treated water 
was added to 1 μL of reaction buffer (10x) [100 mM Tris-HCl (pH 7.5 at 25ºC), 25 mM 
MgCl2, 1 mM CaCl2] and 1 μL of DNase enzyme (1 U/ μL). The reagents were mixed, 
centrifuged to collect drops, incubated at 37ºC for 30 minutes and briefly centrifuged 
again. Then 1 μL of 25 mM EDTA was added, and the solution incubated at 65ºC for 10 
minutes to inactivate the enzyme. After incubation the samples were used as templates 
for reverse transcription. 
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Reverse transcriptase reaction  
Reverse transcription was conducted using the RevertAid First Strand cDNA Synthesis 
Kit (Fermentas, #K1621) according to the manufacturer’s intructions. To the previously 
obtained 11 μL of DNase-treated RNA, 1 μL of oligo (dT)18 primer (0.5 μg/ μL) was 
added. The sample was mixed, briefly centrifuged to collect drops and incubated at 
70ºC for 5 minutes. Then, the mix was cooled on ice and shortly centrifuged. Next, 4 μL 
of reaction buffer (5x) [250 mM Tris-HCL (pH 8.3), 250 mM KCl, 20 mM MgCl2, 50 
mM DTT], 1 μL of RiboLock Ribonuclease Inhibitor (20U/ μL), and 2 μL of dNTP mix 
(10 mM) were added. The mix was briefly centrifuged and incubated at 37ºC for 5 
minutes. Afterwards, 1 μL of RevertAid M-MuLV Reverse Transcriptase (200 U/ μL) 
was added to the mixture, and this was incubated at 42ºC for 60 minutes. To stop the 
reaction, the mix was heated at 70ºC for 10 minutes. Finally, the sample was cooled 
down on ice and stored at -20ºC. 
 
Polymerase chain reaction (PCR)  
For PCR amplification a mix was prepared composed of: 2 μL of DNA sample, 5 μL Go 
Taq Flexi reaction buffer (5x) (without MgCl2), 1.5 μL of MgCl2 (25 mM); 0.5 μL of 
dNTP (10 mM), 1 μL of forward primer and 1 μL of the reverse primer (12.5 μM), 0.1 
μL of GoTaq DNA polymerase (5 U/μL) and sterile deionized water until a final 
volume of 25 μL. All the reagents mentioned above were from Promega with the 
exception of dNTPs (Fermentas). The PCR reaction was performed in a thermal cycler 
(MyCycler, Bio-Rad) with the following program: an initiation step of 95ºC for 2 
minutes, followed by 30 cycles of denaturation at 95ºC for 1 minute, annealing at 55ºC 
for 1 minute and elongation at 72ºC for 30 seconds. A final elongation step of 72ºC for 
5 minutes was also performed. The MUC1 transcript was amplified using the following 
primer sequences, designed using Primer3 software and synthesized by Sigma-Aldrich
:
 
Forward, 5’-GTG CCC CCT AGC AGT ACC G-3’; and Reverse, 5’-GAC GTG CCC 
CTA CAA GTT GG-3’. After PCR amplification, 10 μL of each PCR reaction product 
and 5 μL of 100 pb ladder (Bioron) were loaded into a 2% agarose gel and 
electrophoresed in TAE buffer. The PCR products were visualized with a UV light 
transilluminator attached to a digital camera (Gene FLASH). 
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6.3. REAL-TIME PCR  
For real-time PCR, we used the iQ SYBR
-
Green Supermix kit (Bio-Rad) following the 
manufacturer’s instructions. The cDNA samples obtained as described before, were 
used at a 1/20 dilution. A master mix was prepared for each pair of primers with 9.7 μL 
of H2O, 0.4 μL of forward primer, 0.4 μL of reverse primer (both at 12.5 μM) and 12.5 
μL of SYBRr Green Master Mix (2x). For MUC1 detection we used the primers 
described above. For ACTB detection, used as a reference gene, we used the following 
primers: Forward, 5’-AGG CCA ACC GCG AGA AGA TGA C-3’ and Reverse, 5’-
AGG TCC AGA CGC AGG ATG GCA T-3’ (Villablanca et al., 2008), synthesized by 
Sigma-Aldrich. The master mix was distributed on 96-well ABgene PCR plates 
(Thermo Scientific, AB-0700), 23 μL per well, together with 2 μL of sample cDNA 
(each sample in triplicate). Water was used as negative control. The PCR microplate 
was covered with adhesive PCR film (Thermo Scientific, AB-0558). The real-time PCR 
was performed on a CFX96 Real-Time PCR Detection System (Bio-Rad). Relative 
mRNA expression levels were calculated through the 2
-ΔΔCt
 method (Livak & 
Schmittgen, 2001). 
 
6.4. FLOW CYTOMETRY 
Flow cytometry was performed on trypsinized MCF-7 and MDA-MB-468 cells, 
resuspended in cold PBS. 5x10
5
 cells of each cell line were dispersed by gently 
aspirating with a pipette, placed in each of three 5 ml FACS tube (BD Falcon) and 
resuspended in 1mL of cold FACS buffer [3% Calf Serum (CS) (PAA), 10 mM NaN3 in 
PBS]. Two of the three FACS tubes of each cell line were centrifuged at 300 g for 5 
minutes. The supernatant was discarded, the cell pellet of one FACS tube was incubated 
with 50 μL of C595 antibody (1:100 in FACS buffer) and the other tube with α-tubulin 
antibody (1:500 in FACS buffer). The incubation was carried out for 1 hour. Then, the 
cells were washed twice with 1 mL of FACS buffer and then incubated with 
phycoerythrin-conjugated goat anti-mouse immunoglobulins (GAM-PEs) (Biolegend) 
diluted 1:100 in FACS buffer, in the dark for 30 minutes. As a control group, 5x10
5
 
cells were incubated with GAM-PE only. The cells were washed as above and 
resuspended in 1mL of 10 mM NaN3 in PBS. All the mentioned steps were performed at 
4ºC. Finally the cells were analyzed using the BD FACSCalibur (BD Biosciences) 
equipped with the Cell Quest software package (BD Biosciences). 
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7. ASSESSMENT OF SPECIFIC TARGETING OF BIOCONJUGATED 
MICELLES 
7.1. FLOW CYTOMETRY 
MDA-MB-468 and S17 cells were seeded on 12-well culture plates (6x10
4
 cells/well in 
600 μL of DMEM) and allowed to attach for 24 hours. Then, 200 μL of anti-MUC1-
targeted and non-targeted micelles with encapsulated fluorophore were added to each 
cell line. Cells were incubated with targeted micelles or non-targeted micelles for 15 or 
30 minutes at 37ºC. Untreated cells were used as negative control. After incubation, the 
medium was discarded and the cells were washed 3 times with 1 mL cold PBS. 
Subsequently, the cells were detached with 0.25% trypsin and resuspended in 1 mL cold 
PBS. These samples were filtered through a cell-strainer cap (BD Falcon) to 5 mL 
FACS tubes. The cells were centrifuged at 300 g for 5 minutes and resuspended in 1 mL 
of cold PBS. All the mentioned steps were performed at 4ºC. Finally the cells were 
analyzed using the BD FACSAria II Multicolor cell sorter (BD Biosciences) and data 
were examined by Cell Quest software package (BD Biosciences). Excitation of 1-
methylpyrene was at 407 nm, and the emission spectrum was detected from 430 to 470 
nm. 
 
7.2. FLUORESCENCE MICROSCOPY 
Without cell fixation 
MCF-7 cells were seeded in 96-well culture plates (50 μl in each well with a 
concentration of 5x10
3
 cells per well) and allowed to attach for 24 h at 37ºC. Micelles 
bioconjugated with C595 (25 μl) and loaded with 1-methylpyrene were added to the 
cells and incubated for 1 hour at 37ºC. As a control, we used unconjugated 1-
methylpyrene-loaded polymeric micelles. Excess micelles were removed by washing 
three times with PBS. Microscopy observations of cells before and after micelle 
washing were performed with an inverted fluorescent microscope (Leica DM IL). 
Images were acquired with a digital CCD camera (Evolution MP-5.1, Media 
Cybernetics). Images were processed using Adobe Photoshop CS2 software 
(AdobeSystems).  
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With cell fixation 
Sterile 13 mm glass coverslips (VWR) were placed inside two wells of a 12-well culture 
plate. On one of those wells, MDA-MB-468 and S17 cells were seeded with the 
proportion of 1 to 5; on the other well MFC-7 and S17 cells were seeded with the same 
proportion. To both wells, 600 μL of DMEM medium were added to make a final 
concentration of 6x10
4
 cells per well. The cells were allowed to attach for 24 hours at 
37ºC. Then, 200 μL of anti-MUC1 fluorophore-loaded micelles were added to the cells 
and incubated for 1h at 37ºC. Then, the cells were washed 3 times with 1 mL of PBS 
and fixed with 600 μL of paraformaldehyde (4%) (Sigma-Aldrich) for 30 minutes. The 
cells were washed once with 1 mL of PBS, and each coverslip was collected from the 
wells with forceps and layed onto a microscope slide (Menzel-Glaser) and covered with 
a Mowiol mounting (Hoechst). The glass slides were kept cold overnight. Microscopic 
observations of fixed cells were performed with Axio Observer Z2 Fluorescence 
microscope (Zeiss). Images were acquired with a digital AxioCam (Zeiss) and were 
processed using AxioVision is the software (Zeiss). 
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CHAPTER III: RESULTS 
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1. DEMONSTRATION OF MICELLE pH-SENSITIVE MECHANISM OF 
CONTENT RELEASE  
The pH sensitivity of Gd(III) complex-loaded micelles was visualized in a clinical MRI. 
A T1WI of two microfuge tubes containing Gd(III) complex-loaded micelle solution 
was imaged using a 1.5T MR scanner. 
 
 
 
The sample with intact micelles did not provide an image signal (Figure 13, 
square A). In contrast, the sample at low pH presented a signal enhancement which 
was visible as a bright signal (Figure 13, square B). These results indicate that micelles 
decomposed and released the Gd(III) complexes, allowing them to interact with 
surrounding water molecules, thus decreasing their T1 times and increasing the image 
signal intensity from that specific area.  
 
 
 
A B
Figure 13 – Demonstration of pH-sensitive nanoparticle content 
release. A T1WI was acquired using a clinical 1.5T MRI scanner. 
This image shows the recovery of the imaging capability of the 
contrast agent at low pH, because no image signal was visible from 
the sample with intact nanoparticles (square A) whereas the sample at 
low pH generated a signal enhancement (square B). 
Self-assembled nanoparticles as new smart contrast agents for magnetic resonance imaging  2010 
T. Simão  49 
The pH sensitivity of Gd(III) complex-loaded micelles was also testedin mice.  
 
 
 
Both legs of mouse that had been injected with our pH-sensitive micelles loaded 
with Gd(III) complexes, appeared bright on MR image (Figure 14-A), indicating the 
release of the contrast from the micelles into the leg muscles. The previous 
intramuscular injection of an acidic solution in the right hind leg led to increased signal 
enhancement, indicating that artificially creating an acidic environment facilitated the 
Gd(III) complex release. 
 
 
 
 
 
 
Figure 14 - Demonstration of pH-sensitive nanoparticle content release in in vivo. 
A T1WI was acquired using a clinical 1.5T MRI scanner. This image shows a signal 
enhancement from both hind legs of mouse injected with pH-sensitive micelles loaded 
with Gd(III) complexes (A). A stronger signal was obtained from the right hind leg, 
which was previously injected with an acid solution. A non-injected mouse is shown as 
control (B). 
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2. IN VITRO CYTOTOXICITY TESTS 
To assess the cytotoxicity of free Gd(III) complexes we tested the effect of incremental 
concentrations of two different cell lines, Jurkat, a suspension leukemia cell line, and 
MCF-7, an adherent breast cancer cell line. Toxicity was represented as the number of 
viable cells per mL (Figure 15) or as the percentage of viable cells relatively to the 
control untreated group (Figure 16 and 18). 
 
 
Free Gd(III) complexes were toxic for Jurkat cells at concentrations of 10 to 50 
μM (Figure 15). At 10 μM, the complexes were less toxic for the cells, since even after 
3 days of incubation a slight increase in cell growth was observed. In contrast, at 50 μM 
the complexes were very toxic, causing a progressive cell death with time. 
We also evaluated the cytotoxicity of Gd(III) complexes using the MTT assay, 
another method measuring cell viability, on the Jurkat and MCF-7 cell lines (Figure 16 
and 18). By doing so, we verified that 10 μM of Gd(III) complexes are toxic for both 
cell lines , significantly decreasing the number of viable cells (Figure 16). In order to 
estimate the concentration of Gd (III) complexes able to reduce cell viability by 50% 
(IC50), we plotted a linear regression line for each cell line studied (Figure 17). Thus, the 
IC50 for the MCF-7 cell line was 12.8 μM of Gd(III) complexes (Figure 17-A). For 
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Figure 15 – Cytotoxicity of free Gd(III) complexes by cell count. Comparison 
of cytotoxicity of varying concentrations of Gd(III) complexes using cell count 
with Trypan Blue on Jurkat cell line, during 3 days. Data represent the means of 
duplicate ± standard deviation. 
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Jurkat cells the IC50 was 10.2 μM of Gd(III) complexes (Figure 17-B). It appears thus 
that Jurkat cells are slightly more susceptible to Gd (III) complexes than MCF-7 cells.  
 
 
 
Figure 16 – Cytotoxicity of free Gd(III) complexes by MTT assay. Comparison of cytotoxicity of varying 
concentrations of Gd(III) complexes using MTT assay on MCF-7 (A) and Jurkat (B) cell lines. The test was 
performed at the end of 3 days of treatment. Data represent the means of eight testes + standard deviation. 
 
 
 
Figure 17 – Linear regression line for cytotoxicity of free Gd(III) complexes. A linear regression line was 
calculated from data obtained by MTT assay, to be used as a standard curve to find the concentrations of Gd(III) 
complexes to reduce cell viability to 50% of control values for MCF-7 (A) and Jurkat (B)  cell lines.  
 
 
To compare the cytotoxicity of free and micelle-encapsulated Gd(III) complexes 
and to verify if the time of dialysis influences polymeric micelle cytotoxicity, we 
performed the MTT assay on Jurkat cells. The cells were treated with incremental 
concentrations of the free and micelle-encapsulated Gd(III) complexes. Thus, we 
verified that encapsulation of Gd(III) complexes inside polymeric micelles greatly 
decreased their toxicity (Figure 18). The difference in cytotoxicity was most evident at 
50 μM, the highest concentration tested. At this concentration, encapsulated Gd(III) 
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complexes reduced viability to approximately 70-85% of untreated controls, while free 
Gd(III) complexes killed almost all cells (Figure 18).  
 
 
 
 
Micelles presented at both concentrations significantly less cytotoxicity than free 
Gd(III) complexes. Micelles that were maintained under dialysis for 4 days were 
significantly less toxic at 50 μM than those maintained in dialysis for 1 day. However at 
low concentration (10 μM) the difference in cytotoxicity between the two micelle 
formulations is not significant (Figure 18). This experiment confirmed that 50 μM of 
Gd(III) complexes kill all cells, as previously verified by cell counting (Figure 15).  
 
3. ANALYSIS OF MUC1 GENE AND PROTEIN EXPRESSION 
Once verified the pH-dependent release mechanism and the little cytotoxicity of the 
Gd(III)-loaded nanoparticles, we wished to develop micelles bioconjugated with an 
anti-human MUC1 MAb (C595) to use them for active targeting. However, before 
initiating specific targeting tests, we verified the levels of MUC1 gene and protein 
Figure 18 – Cytotoxicity comparison of free and nanoparticle-encapsulated Gd(III) complexes. Comparison of 
cytotoxicity of low (10μM) and high (50μM) concentrations of free and nanoparticle-encapsulated Gd(III) complexes 
using MTT assay on Jurkat human leukemia cell line, after 3 days of incubation . Micelles dialyzed for 4 days were 
compared with micelles dialyzed for 1 day. Data represent the means of quadruplicate + standard error of the mean 
(***p ≤ 0.0001; ns, nonsignificant).  
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expression in the cell lines used for targeting. MUC1 mRNA expression was assessed 
by both standard and quantitative RT-PCR, whereas MUC1 protein expression was 
detected by Western Blotting and flow cytometry (Figures 19 to 22). (The 
concentration, purity and quality of RNA isolated from the different cell lines are 
available on appendix A. 
 
 
RT-PCR analysis revealed MUC1 gene expression not only in the MDA-MB-
468 and MCF-7 human breast adenocarcinoma cells but also in other epithelial cell 
lines, such as Hela, 293T, ARPE19 and D407 (Figure 19). MDA-MB-468, MCF-7 and 
Hela cells appeared to present stronger RT-PCR signal, compared to ARPE19, D407 
and 293T cells. To assess more accurately the expression of MUC1 in the different cell 
lines we performed real-time RT-PCR. 
Figure 19 – Detection of MUC1 expression by RT-PCR. MUC1 mRNA was expressed by all used cell 
lines; the highest expression was shown by MDA-MB-468 cells. DNA marker (100-600 bp ladder). 
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By doing so, we verified that MDA-MB-468 presented the highest levels of 
MUC1 expression, when compared to the other cell lines (Figure 20). Hela and MCF-7 
cell lines showed similarly high levels of MUC1 expression, while the ARPE 19 and 
D407 retinal epithelial cell lines displayed reduced expression of MUC1. The human 
embryonal kidney 293T cell line had residual expression as compared to other cell lines. 
To confirm the RNA expression studies and detect MUC1 protein expression, 
we performed Western Blotting and flow cytometry. We analyzed the DND41 and 
MCF-7 cell lines by Western Blot. The α-tubulin detection by Western blotting is 
shown in appendix B. 
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Figure 20 – MUC1 relative expression, in different cell lines, by real-time PCR analysis. The 
highest MUC1 expression was shown by MBA-MB-468 human breast adenocarcinoma cell line, 
when compared to other examined cell lines. 
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Western blotting using the C595 MAb revealed the expected high-molecular-
weight polymorphic MUC1 bands (Figure 21), demonstrating the presence of protein in 
MCF-7 homogenates. DND41 also expressed MUC1 protein. However, since this cell 
line presented just one band, only one isoform of MUC1 is present.  
To verify the presence of MUC1 protein at the cell surface of breast cancer cell 
lines and to compare the expression levels between MDA-MB-468 and MCF-7 cells, we 
performed flow cytometry using the C595 antibody and a fluorophore-conjugated 
secondary antibody. 
 
Figure 22 – Analysis by fluorescent flow cytometry to detect MUC1 cell surface expression on MCF-7 and 
MDA-MB-468 cell lines. MUC1 expression was detected on both cell lines using the anti-MUC1 extracellular 
domain, C595 MAb (black line). The discontinuous black line indicates reactivity with an irrelevant antibody of the 
same isotype. The grey shaded region is the control group.  
 
Figure 21 – Detection of MUC1 glycoprotein in homogenates of 
MCF-7 breast cancer cells and DND41 acute lymphoblastic 
leukemia cells by SDS-PAGE and Western Blotting. The reaction 
with anti-MUC1 antibody confirmed the presence of MUC1 in MCF-7 
homogenates. 
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The C595 antibody conferred more fluorescence signal to the cell lines than an 
irrelevant antibody, indicating that the MUC1 protein is expressed at the cell surface of 
MCF-7 and MDA-MB-468 cell lines (Figure 22). The MUC1 cell surface expression 
levels were higher for MDA-MB-468 cells than for MCF-7 cells (Figure 22), which 
confirms results obtained with quantitative RT-PCR. 
 
4. ASSESSMENT OF SPECIFIC TARGETING OF BIOCONJUGATED 
NANOPARTICLES 
An important feature of the designed nanoparticles, besides the pH-sensitive release 
mechanism, is the ability to specifically target MUC1-expressing cells. This 
characteristic should prevent the random accumulation of these nanoparticles on 
undesired tissues, and confer a real target capability to these nanoparticles. To test this 
property we used 1-methylpyrene fluorophore loaded into micelles instead of Gd(III) 
complexes, because of the feasibility of fluorescence detection in cells. The first step 
towards this aim was to bioconjugate fluorophore-loaded micelles with the anti-MUC1 
antibody, C595. The next step was to verify the capability to specifically target MUC1-
expressing cells.  
For targeting experiments and flow cytometry detection of 1-methylpyrene 
incorporation, we used the MDA-MB-468 cell line, which displayed the highest levels 
of MUC1 expression (Figure 22), and the S17 cell line, which derives from mouse bone 
marrow stroma. Since the antibody used against MUC1 is specific for the human 
protein, the S17 mouse cells were used as a negative control. For this experiment, 
bioconjugated and non-targeted fluorophore-loaded micelles were incubated for 
different periods of time with both cell lines. Before analysis, the cells were thoroughly 
washed to eliminate unbound nanoparticles. 
Self-assembled nanoparticles as new smart contrast agents for magnetic resonance imaging  2010 
T. Simão  57 
 
 
Table 1 – Delta (∆) values. Those values represent the fraction of cells (in percentage) which showed a fluorescent 
intensity enhancement due to uptake or attach of 1-methylpyrene loaded nanoparticles. 
 
 
Incubation Time 
(minutes) 
S17 cells MDA-MB-468 
Non-targeted 
micelles 
Anti-MUC1 
micelles 
Non-targeted 
micelles 
Anti-MUC1 
micelles 
15 0.8% 2.17% 2.06% 6.34% 
30 2.07% 2.3% 0.74% 8.41% 
Figure 23 – Fluorescent flow cytometry to assess specific targeting of Anti-MUC1 bioconjugated 1-
methylpyrene loaded nanoparticles. An enhancement in fluorescence intensity is evident on MDA-MB-468 cells 
which were incubated for 15 minutes and for 30 minutes with Anti-MUC1 bioconjugated nanoparticles (gray shaded 
region) comparing with S17 cells. The black shaded region indicates the fluorescent enhancement due to cell 
incubation with non-targeted 1-methylpyrene loaded nanoparticles. Delta symbol (∆) designates the fraction of cells 
that showed a fluorescent intensity enhancement due to uptake of 1-methylpyrene-loaded nanoparticles. Delta values 
are presented on table 2. 
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MDA-MB-468 cell incubation with C595 bioconjugated micelles led to a higher 
percentage of fluorescent cells than incubation with nontargeted micelles (Figure 23; 
Table 1). In contrast, incubation of C595 bioconjugated micelles did not increase the 
proportion of fluorescent S17 cells, which do not express human MUC1, as compared to 
nontargeted micelles. The superior target capability and consequent fluorescence 
enhancement in MUC1-expressing MDA-MB-468 cells, was demonstrated by the 
fluorescent enhancement of 6.3-8.4%. Despite the improved uptake of 1-methylpyrene 
by MUC1-expressing MDA-MB-468 cells, we also observed some degree of unspecific 
uptake, as demonstrated by the presence of approximately 2% fluorescent S17 cells 
after incubation with either C595-conjugated or unconjugated micelles, and 2% 
fluorescent MDA-MB-468 cells after incubation with non-targeted micelles (Table 1).  
We also aimed to visualize by fluorescence microscopy 1-methylpyrene 
incorporation into cells upon incubation with micelles loaded with this fluorophore. 
MCF-7 cells were incubated for 1 hour with targeted and non-targeted micelles, and 
then observed using an inverted fluorescence microscope. MCF-7 cells incubated with 
anti-MUC1 micelles presented more fluorescent staining than cells incubated with non-
targeted micelles (Figure 24). 
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Figure 24 – Specific binding of anti-MUC1 1-methylpyrene-loaded micelles to MCF-7 breast cancer cells. At 
the end of an incubation period of 1 hour, it was evident the differential uptake of non-targeted and anti-MUC1 
micelles by MCF-7 cells.  
Figure 25 – Specific binding of anti-MUC1 1-methylpyrene-loaded micelles to MCF-7 breast cancer cells, after 
washes.  After washing 3 times high 1-methylpyrene fluorescence was found in cells incubated with anti-MUC1 
polymeric micelles, while a low level of background fluorescence was visible in MCF-7 cells incubated with non-
targeting micelles. 
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MCF-7 cells were also observed after washing with PBS, and again cells 
incubated with anti-MUC1 micelles presented much higher fluorescence levels than 
cells incubated with non-targeted micelles (Figure 25). Together, these results 
demonstrate the specificity of the targeted nanoparticles to MUC1-expressing cells and 
demonstrate that micelles release their content within cells.  
Next we used another approach to test the specificity of anti-MUC1 micelles. 
The goal here was to observe if anti-human MUC1 nanoparticles were able to 
specifically target MDA-MB-468, even when these cells were mixed in a lower 
proportion (1 to 5) with mouse S17 cells. The mixed culture was incubated with anti-
MUC1 polymeric micelles for 1 hour and washed several times with PBS before 
observation at the fluorescence microscope. By doing this, we observed that MDA-MB-
468 cells, which display rounded morphology (Figure 26-B), incorporated more 1-
methylpyrene fluorescence (Figure 26-A) than S17 cells, which display elongated 
morphology (Figure 26-C). Indeed, round (MDA-MB-468) cells presented bigger and 
brighter spots than elongated (S17) cells in the mixed cultures (Figure 26-A). 
 
 
Figure 26 – Increased targeting of anti-MUC1 1-methylpyrene-loaded micelles to MDA-MB-468 breast cancer 
cells. MDA-MB-468 (B) and S17 (C) cells were seeded with the proportion of 1:5 and incubated for 1 hour with anti-
MUC1 bioconjugated micelles. After incubation and cell fixation, it was evident the increased uptake of anti-MUC1 
micelles by the human MUC1-expressing MDA-MB-468 cells (A).  
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5. Gd(III) COMPLEXES AND FLUOROPHORE CONCENTRATIONS IN 
MICELLE SOLUTIONS 
 Although the initial amount of Gd(III) complexes or 1-methylpyrene used to synthesize 
the loaded micelles was known, a fraction of the initial quantity was likely not 
encapsulated within micelles and was eliminated from the final nanoparticle solution 
during dialysis. Thus, to estimate the effective concentration of Gd(III) complexes or 1-
methylpyrene encapsulated within nanoparticles during self-assembly, we performed a 
calibration curve plotting the concentration of Gd(III) complexes or 1-methylpyrene and 
its absorbance spectrum (Figure 27 and 28, respectively).    
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Figure 27 – Calibration curve for Gd(III) complexes. By measuring absorbances of six 
Gd(III) complex solutions of different concentrations a calibration curve was obtained to 
estimate the concentration of Gd(III) complex in unknown samples. 
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Using the obtained calibration curve for 1-methylpyrene, we measured the 
concentration of bioconjugated and non-targeted 1-methilpyrene-loaded micelle 
samples (Table 2). Since to obtain the concentration data presented on Table 2 the 
micelle samples were diluted 100 times, the real concentration of 1-methylpyrene 
present on the original solutions of non-targeted 1-methylpyrene loaded micelles was 
1.61x10
3
 μM, while the concentration of the original solution of bioconjugated micelles 
was 8.3x10
2
 μM. Therefore, the solutions containing bioconjugated micelles that we 
used for cell targeting were approximately half the concentration of nontargeted 
micelles. 
 
Table 2 – Absorbance measurements of 1-methylpyrene-loaded micelle solutions.  
 
 
Sample Absorbance Concentration (μM) 
Fluorophore-loaded micelles 0.4847 16.1 
Bioconjugated fluorophore-loaded micelles 0.2509 8.3 
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Figure 28 – Calibration curve for 1-methylpyrene. By measuring absorbances of six 1-
methylpyrene solutions of different concentrations, a calibration curve was obtained to estimate 
the concentration of 1-methylpyrene in unknown samples. 
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CHAPTER IV: DISCUSSION 
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One of the greatest challenges in medical imaging is to detect cancer early. This has 
been the major factor in improving successful therapy, in reducing mortality, and 
reducing cancer management costs (Fass, 2008). Smart CAs seems to offer a significant 
improvement for disease detection because these agents change their conformational 
state in the presence of specific stimuli. The change is detected as an alteration in the 
MR image signal. The smart CAs might detect a change in pH, which is a common 
feature of cancerous tissues and occurs early during tumor development (Hartman et al., 
2008). 
Contributing for early cancer detection, we have developed a new MRI contrast 
agent composed of pH-sensitive micelles with encapsulated hydrophobic Gd(III) 
complexes. These micelles were bioconjugated with an antibody to target the MUC1 
protein, which is a valuable early cancer biomarker (Cheng et al., 2009). 
During this research project we have demonstrated that: i) encapsulation of 
Gd(III) complexes within micelles abrogated their cytotoxicity; ii) micelles loaded with 
Gd(III) complexes released their content at low pH; and iii) micelles conjugated with an 
antibody against the MUC1 cell surface protein displayed increased affinity for cultured 
human breast cancer cells expressing high levels of this protein, than for other cells. 
 
1. NANOPARTICLE SIZE AND pH STABILITY 
Important features in nanoparticles production are the achievement of a certain particle 
size with a narrow size distribution and a good stability (Galindo-Rodriguez, Allémann, 
Fessi, & Doelker, 2004). The new micelles possessed these characteristics. 
The small micelle size is important, because extravasation of nanoparticles from 
blood vessels into tissues and endocytosis by cells are dependent on nanoparticle size. 
Yuan and colleagues suggested that the limit size for liposomes extravasation from 
blood vessels into tumors was approximately 400 nm (Yuan et al., 1995), whereas other 
authors demonstrated that sizes inferior to 200 nm are more efficient (Hobbs et al., 
1998). Others reviewed that nanoparticles with sizes smaller than 100 nm should be 
preferably used to tumor targeting as they are small enough to escape clearance by 
macrophages from liver and spleen, and thus are able to circulate long enough to 
extravasate through fenestrated tumor vasculature (Couvreur & Vauthier, 2006). 
Regarding the cellular uptake of ligand-coated nanoparticles it has been demonstrated 
that nanoparticle diameters below 50 nm presented a greater uptake by cells compared 
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with particles with larger diameters (Gao, Shi, & Freund, 2005). Also Zhang and 
coworkers theoretically demonstrated that the uptake rate reaches a maximum 
approximately at diameters of 50 nm, which was in agreement with others experimental 
studies (Zhang, Li, Lykotrafitis, Bao, & Suresh, 2009).  
Since the size of the newly created micelles was estimated to be of 
approximately 24 nm (see Introduction; Figure 3), these nanoparticles are therefore 
suitable to be maintained in the blood flow until crossing the leaky cancer vessels, 
accumulate at interstitial spaces, remain here long enough to allow disassembly and 
release of the contrast agent in the presence of low pH. It should thus be possible to 
obtain an image signal from this specific pathological area. 
Cancer tissues are characterized by an acidic microenvironment, with 
extracellular pH values ranging from 6.2-6.9 (Gillies et al., 2002). The performed tests 
undoubtedly demonstrated that micelles disassembled at pH values near 4-5 and were 
stable at pH=7. The micelles also released the CA into the hind leg muscles without the 
presence of the acid solution. However the injected mouse was quite agitated before 
being anesthetized. Exercising to exhaustion decreases skeletal muscle pH to around 6.6 
(Harmer et al., 2000), thus maybe this pH decrease could caused micelles disassembled. 
Additional tests to better characterize micelle stability at pH range between 4 to 7 
should be performed in order to accurately establish the threshold pH for micelle 
disassembly. 
 
2. Gd(III) COMPLEX AND MICELLE CYTOTOXICITY 
The IC50 of the newly synthesized hydrophobic Gd(III) complexes ranged from 10.2-
12.8 μM depending of the used cancer cell line. At 50 µM Gd(III) complexes killed 
most cells after 3 days in culture. However, when the Gd(III) complexes were entrapped 
inside micelles, the toxicity was almost absent, even after 3 days of in vitro incubation. 
This means that the micelles prevented cells from Gd(III) complex toxicity. 
The protection from content toxicity provided by these micelles is important for 
their administration as nanocarriers in in vivo studies. This allows reduced toxicity to 
non-disease tissues, at least until micelles reach the appropriate environment and 
disassemble. Nevertheless, further tests should be performed to compare the toxicity of 
our hydrophobic Gd(III) complexes with that of other Gd-based CAs commercially 
available, and to verify if our smart CA has clinically acceptable toxicity levels, 
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especially because after release from micelles the CA will be potentially toxic for 
healthy tissues during body elimination. When comparing the IC50 of 10.2-12.8 µM of 
our Gd(III) complexes with the the IC50 greater than 100 μM achieved by HPMA-
(DOTA-Gd] complexes and the IC50 of approximately 1000 μM achieved by a 
commercially available CA (Zarabi, Nan, Zhuo, Gullapalli, & Ghandehari, 2008), we 
conclude that our contrast agent has increased cytotoxicity. 
To avoid excessive Gd(III) release and harmful accumulation in body tissues, 
the Gd(III) chelating system should be stable (Bushong, 2003, pp.365-373). Researchers 
that attached Gd(III)-based CAs to the surface of nanoparticles had also to increase the 
stability of the chelating system of their CAs, as compared to commercially available 
LMWCAs (Winter et al., 2008). More stable Gd(III) chelation was necessary because 
having targeted nanoparticles higher circulating times than LMWCAs, the CAs attached 
to the surface of nanoparticles have an increased probability of encountering competing 
species (metal centers) that cause the exchange of ligands, a reaction designated as 
transmetallation (Winter et al., 2008). In our case, a stability of the chelating system 
equivalent to that of commercially available LMWCAs appears sufficient, because the 
CA will be encapsulated inside micelles, so preventing access to competing species and 
therefore avoiding transmetallation, at least until micelles disassembled in the target 
tissue. Only when micelle disassembly occurs in the body and the Gd(III) complex is 
eliminated, the CA is expected to be susceptible to transmetallation. 
As our toxicity study showed, micelles seemed to be stable at least for 3 days in 
vitro. During the incubation time the micelles were in close contact with cells and 
culture media. Thus we expect that in in vivo studies the nanoparticles that do not reach 
their target will be stable long enough to be eliminated without leakage of CA. 
However, before proceeding to in vivo tests it is important to investigate the micelle 
stability in the presence of plasma proteins and body temperature. 
We have observed slightly higher, but statistically significant cytotoxicity 
caused by micelles dialyzed for 1 day, as compared to micelles dialyzed for 4 days. This 
finding indicates that not all of the initial amount of Gd(III) complexes were 
encapsulated and more than 1 day of dialysis is required to wash off any unencapsulated 
Gd(III) complexes. 
Two different cell lines were used for the cytotoxicity experiments, and we 
verified that the MCF-7 breast adenocarcinoma cell line showed always a higher 
percentage of viable cells for each used Gd(III) complex concentration than Jurkat 
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leukemic cells. This differential susceptibility could be due to different genetic origins 
and characteristics of the cell lines. Supporting this idea, an experimental study to assess 
the cell-type-dependent sensitivity to UV-induced apoptosis showed that after exposure 
to UV irradiation Jurkat cells exhibited faster apoptotic death than MCF-7 cells (Suzuki, 
Akimoto, Sasai, & Yajima, 2003). 
 
3. MUC1 GENE AND PROTEIN DIFFERENTIAL EXPRESSION BETWEEN 
CELL LINES 
MUC1 was chosen as a target for this new MRI CA due to its great potential for early 
detection and staging of tumors, as well as for the assessment of tumor responses to 
therapy and detection of disease recurrence (Kufe, 2009). In addition, the tumoral 
expression of this protein can be useful for breast cancer differential diagnosis and 
prognosis (Medarova, 2009).  
This potential is based upon the observation that MUC1 is up-regulated in 
almost all human epithelial cell adenocarcinomas, in few non-epithelial cancer cell lines 
and in some hematological malignancies (Kufe, 2009; Moore et al., 2004), so MUC1 
overexpression is a very frequent phenomenon in cancer. MUC1 is also 
underglycosylated and ubiquitously expressed throughout the cancer cell surface. The 
diminished MUC1 glycosylation exposes new epitopes that allow the development of 
targeting ligands that selectively recognize cancer cells (Ferreira et al., 2008). The 
MUC1 extracellular domain protrudes 200-500 nm above the plasma membrane, 
making it an easy target for imaging targeted nanoparticles (Gendler, 2001). 
Underglycosylated MUC1 was shown to be overexpressed throughout the tumor life 
and has been detected on primary tumors, as well as on metastases (Medarova, 2009), 
so it can be a valuable marker for the detection of not only early cancers but also 
recurring or metastatic cancer.  
Concerning breast cancer in particular, MUC1 is expressed in more than 90% of 
cases (Mahanta et al.; 2008). Immunohistochemical studies revealed membranar 
expression of MUC1 in benign breast lesions and in DCIS and only poorly 
differentiated lesions of DCIS showed underglycosylated MUC1. It was reported that 
membranar expression of MUC1 decreases cell–cell and cell–extracellular matrix 
interactions (Zhao et al., 2009). Consequently this alteration may facilitate the evolution 
of pre-invasive lesions such as DCIS to invasive cancers and ultimately to metastases. 
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Furthermore, MUC1 is often underglycosylated in invasive carcinomas, so detection of 
underglycosylated MUC1 in pre-invasive breast lesions such as DCIS may be predictive 
of a higher risk of evolution to invasive carcinoma (Mommers et al., 1999).  
MUC1 expression could be correlated with stage progression because in 
different cancer progression stages, MUC1 displayed distinct molecular features such as 
increased expression, deglycosylation and alterations in its cell localization. For 
example benign breast lesions demonstrated slightly elevated levels of MUC1, as 
compared to healthy tissues, but higher levels were detected in more advanced stages of 
breast cancer, and in the underglycosylated form (Medarova, 2009). 
 Since MUC1 protein is expressed in the great majority of breast cancers, it is 
more advantageous for targeting approaches than other proteins such as HER2, which is 
overexpressed in only 20–30% of breast cancers (Sood, 2009). 
To perform targeting studies it was important to detect and compare the 
expression levels of MUC1 gene and protein in different cancer cell lines. In agreement 
with the notion that MUC1 is overexpressed in almost all human adenocarcinomas as 
well as in some hematological malignancies, we found MUC1 gene and protein 
expression in all cancer cell lines tested with the exception of the HEK293T cell line, 
which showed only residual gene expression. This cell line has been used as negative 
control for MUC1 protein detection (Mahanta et al.; 2008), so the residual gene 
expression obtained was expected. In another experimental work, authors performed 
immunocytochemistry to assess the specific binding of newly created recombinant 
antibody fragments against MUC1 expressed in breast, colon and ovarian cancer cell 
lines (Rahbarizadeh et al.; 2004). These antibody fragments revealed a differential 
expression of MUC1 between cell lines, and found also higher expression of this protein 
in MDA-MB-468 cells than in another breast cancer cell line, the MCF-7 cells 
(Rahbarizadeh et al.; 2004). Other researchers also reported quite high levels of MUC1 
protein expression in the MDA-MB-468 cell line (Schroeder, Adriance, Thompson, 
Camenisch, & Gendler, 2003). These diferences in MUC1 expression levels between 
MDA-MB-468 and MCF-7 cells were confirmed by our both experiments detecting 
MUC1 gene and protein. Western blotting was only performed for MCF-7 cells, so 
additional experiments have to be performed to detect MUC1 on MDA-MB-468 cell 
line and compare its levels with those from MCF-7. Nevertheless, protein surface 
expression, which is more interesting for our work than total cellular expression, was 
demonstrated for both breast cancer cell lines by flow cytometry. 
Self-assembled nanoparticles as new smart contrast agents for magnetic resonance imaging  2010 
T. Simão  69 
To target MUC1 we used the mouse monoclonal antibody C595, which reacts 
with the tetrameric motif, RPAP, present on the VNTR region of the MUC1 protein 
extracellular domain. This antibody proved to be an efficient and specific targeting 
vector in in vitro studies, in preclinical and clinical trials of radioimmunoscintigraphy 
and radioimmunotherapy (Song et al., 2008; Simms, Price, Scholfield, & Bishop, 2001; 
Murray et al., 2001). This antibody was first developed to detect mucins in the serum of 
cancer patients because it was found in clinical studies that the levels of epithelial 
mucins in the blood were particularly elevated in patients with metastatic disease from 
breast cancer (Price, 1988). Another study verified that normal urine was an abundant 
source of epithelial mucins, so the MAb C595 (IgG3) was raised against the protein 
core of human urinary epithelial mucin (Price, et al., 1987). The authors of these work 
concluded that the C595 epitope was present in normal and malignant tissues (Price, et 
al., 1990), and was therefore not ideal to detect differentially cancer from normal cells. 
Consequently this antibody is not specific for underglycosylated MUC1, which 
is the most frequent form of MUC1 on cancer cell surfaces. Regarding our flow 
cytometry determination of MUC1 protein expression at the cell surface, we found that 
MUC1 was expressed in MCF-7 and MDA-MB-468 cells, but however at levels lower 
than those observed in other reports using antibodies that may have a greater specificity 
to underglycosylated MUC1 (Akewanlop et al., 2001; Walsh, Luckie, Cummings, 
Antalis, & McGuckin, 2000). This suggests that the C595 antibody we used detects 
weakly MUC1 expressed in cancer cells, which is underglycosylated, and rather detects 
fully glycosylated MUC1 expressed in normal cells. So, if we use the C595 antibody for 
in vivo targeting studies of MUC1-positive breast cancers, perhaps the detection 
efficiency will not be optimal. The MUC1 N-terminal domain is normaly shedded from 
the cancer cell surface and consequenlty high amounts of this subunit are found in the 
blood. Therefore, the C595-conjugated micelles would first interact with shedded 
MUC1 in the circulation and would not interact efficiently with underglycosylated 
MUC1 on the surface of cancer cells (Kufe, 2009). In addition, the targeted 
nanoparticles bound to shedded MUC1 would be quickly cleared from the circulation 
(Kufe, 2009).  
Most commercially available antibodies react against the core protein epitopes 
that include the sequence PDTRPAP (Rahbarizadeh, et al., 2004). The C595 MAb that 
we used recognizes the sequence RPAP, which is adjacent to the threonine that 
undergoes glycosylation. In cancer cells the threonine residue is underglycosylated and 
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is exposed. Since in underglycosylated MUC1 the APDTRP sequence is exposed and is 
immunogenic, several monoclonal antibodies against this sequence have been 
developed. For example the SM3 monoclonal antibody, which recognizes the PDTRP 
sequence (Burchell, Taylor-Papadimitriou, Boshell, Gendler, & Duhig, 1989), has been 
found to  react specifically against breast carcinomas but not benign lesions (Burchell, 
et al., 1987). 
Because underglycosylated MUC1 is very frequent and specific for breast 
cancer; antibodies specific for underglycosylated MUC1 should be used in future 
experiments. Monoclonal antibodies have several advantages for cancer cell targeting. 
They contain two binding sites, which provide a higher binding avidity for the target 
antigen. The antibodies can also induce signaling cascades that kill cancer cells (Carter, 
2001). 
 
4. BIOCONJUGATION OF NANOPARTICLES POTENTIATES TARGETING 
TO MUC1-EXPRESSING CELLS  
Our experiments performed to assess the specific targeting of bioconjugated micelles 
showed that their uptake by cells expressing the MUC1 was higher than uptake of non-
targeted micelles.  
The increased cell internalization of targeted nanoparticles has been verified in 
other studies using different receptors for targeting, and was shown to be due to 
receptor-mediated endocytosis (Lee et al., 2003; Gao et al., 2005; T. Chen et al., 2009). 
Some degree of nonspecific uptake was detected, which could be due to pinocytosis 
after the adsorption of the nanoparticles to the cellular membrane. Non-specific uptake 
in vitro can be influenced by surface charge and concentration of the nanoparticles as 
well as by the incubation time with cells (Panyam & Labhasetwar, 2004). However 
further tests will have to be conducted to prove that the brighter fluorescence spots 
observed in cells targeted with micelles are endocytic vesicles (endosomes and/or 
lysosomes). 
The results obtained by fluorescence microscopy and flow cytometry indicate 
that micelle bioconjugation with a MUC1 antibody increased targeting to MUC1-
expressing cells. However, several experimental aspects need to be improved to 
quantify more accurately the specificity of bioconjugated micelles and to obtain more 
statistical support. An issued to be improved for all procedures is to obtain a more 
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accurate estimation of the concentration of 1-methylpyrene as well as the micelle 
aggregation number for targeted and non-targeted micelles. By doing this, we will use 
equivalent concentration of both types of micelles in experiments. The experiments 
presented in this thesis were performed with the same amount (μL) of each micelle 
colloid prepared in parallel, which did not mean exactly the same concentration of 
micelles. After micelle synthesis it appeared that each sample had different 
concentrations of nanoparticles due to their different turbidity. The non-targeted micelle 
dispersion was visibly more turbid than that from targeted micelles, so we assume that 
the former were more concentrated than the latter. Turbidity appears because the 
nanoparticles scatter light (Bhalerao, Sinha, Srivastava, & Srivastava, 2009). However, 
this assumption requires confirmation. 
To test the specificity of C595-conjugated 1-methylpyrene-loaded micelles we 
incubated these with MDA-MB-468 and S17 cells, and found that MDA-MB-468 cells 
incorporated more fluorescence than the latter. This result was based on the observation 
that the MDA-MB-468 breast cancer cells have different morphology than S17 cells. 
Since morphological observation is not very accurate, we could not quantify the 
percentage of targeted cells. To be able to do this, we plan to stain MDA-MB-468 cells 
with a red fluorescence before mixing these cells with unstained S17 cells. After 
incubation with C595-conjugated 1-methylpyrene-loaded micelles, percentage of red 
fluorescent cells that also present 1-methylpyrene fluorescence will be estimated. 
 
5. Gd(III) COMPLEXES AND FLUOROPHORE CONCENTRATIONS IN 
MICELLE SOLUTIONS 
To estimate the concentration of micelles in solutions, we created calibration curves for 
Gd complexes and 1-methylpyrene. By doing this, we could estimate that non-targeted 
1-methylpyrene-loaded micelle solutions were more concentrated than targeted 
micelles. This result is therefore in agreement with the observation that non-targeted 
micelle solutions were more turbid than targeted micelles. In addition, using these 
calibrations curves, it will be possible to estimate the concentration of 1-methylpyrene 
and Gd(III) complexes loaded in micelles, before undertaking further in vitro and in 
vivo tests. The accuracy of these measurements will not be however fully accurate due 
to the fact that not all non-encapsulated compounds will be washed off by dialysis. 
Concerning the Gd (III) complexes, it will be necessary to verify the amount which is 
Self-assembled nanoparticles as new smart contrast agents for magnetic resonance imaging  2010 
T. Simão  72 
encapsulated and to measure the T1 relaxivity of these newly synthesized hydrophobic 
Gd(III) complexes before proceeding to in vivo studies. It is important to use equivalent 
concentrations to those recommended clinically in order to compare the performance of 
this new contrast agent with others in research or commercially available. 
In conclusion, this work demonstrated that this new designed micelles 
successfully encapsulate hydrophobic Gd(III) complexes or fluorescent dyes and 
preventing cytotoxicity caused by Gd(III) complexes. These nanoparticles proved to be 
able to release their content exclusively at low pH environments, causing a signal 
enhancement in MR T1-weight images, and were effectively bioconjugated with the 
C595 MAb. 
Conjugation with this antibody potentiated the specific attachment of micelles to 
the target cells in vitro. Therefore our results support the notion that these self-
assembled nanoparticles are suitable to be used as MRI contrast agents, by passively 
and actively targeting cancerous cells. We expect these nanoparticles to increase MRI 
sensitivity in early breast cancer detection and to improve tumor staging as well as 
assessment of tumor responses to therapy. 
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CHATER V: FUTURE PERSPECTIVES 
 
 
 
 
 
 
 
 
 
 
 
 
Self-assembled nanoparticles as new smart contrast agents for magnetic resonance imaging  2010 
T. Simão  74 
This work describes preliminary data indicating the suitability of this new contrast agent 
for MRI detection of breast cancer. To reach the final goal, which is to develop a 
product that can be clinically useful, there are still several experiments to perform. 
1) The nanoparticles here described detect glycosylated MUC1 protein. Since 
underglycosylated MUC1 is characteristic of cancers, we will verify whether an 
antibody specific for underglycosylated MUC1 (SM3 monoclonal antibody) detects 
MDA-MB-468 and MCF-7 breast cancer cells with higher affinity than the C595 
antibody. 
2) For further in vitro and in vivo experiments, it will be important to have more 
information about the size, stability and concentration of synthesized nanoparticles. To 
this end, we will carry out additional characterization tests concerning size; micelle 
aggregation number, payload and encapsulation efficiency of Gd(III) complexes or 1-
methylpyrene fluorophore. To estimate the stability of nanoparticles in the blood 
circulation and in body tissues, we will verify their stability in the presence of physico-
chemical conditions mimicking blood circulation, i.e. pH, temperature and serum 
proteins. 
3) To test the efficiency of the SM3 antibody for targeting micelles to breast 
cancer cells expressing underglycosylated MUC1, micelles will be conjugated with this 
antibody. Then, SM3-conjugated and non-conjugated micelle concentration will be 
estimated and then equal concentrations will be incubated with breast cancer cell lines 
to quantify their targeting ability by fluorescence microscopy and flow cytometry. For 
fluorescence microscopy experiments, MUC1-expressing cancer cells stained with a red 
fluorescence dye will be used to accurately distinguish them from MUC1-negative cells 
and so determine which cells incorporate 1-methylpyrene. In addition, we will use 
fluorescent dyes that specifically stain different endocytic vesicles to understand better 
the nanoparticle uptake mechanism. 
4) To determine the targeting ability of antibody conjugated and unconjugated 
nanoparticles, we will implement an MDA-MB-468 breast cancer xenograft mouse 
models. Tumors will develop in these mice and after nanoparticle injection in their 
circulation, MRI is going to be performed to detect cancer cells. 
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5) To know the in vivo behavior of our newly developed targeted and non-
targeted nanoparticles, the pharmacokinetics, release mechanism and the active in vivo 
targeting of MUC1-expressing mouse tumors will be determined using 1.5T MRI. 
6) To verify whether this contrast agent can be used universally for cancer 
detection, we will conjugate nanoparticles with an antibody recognizing another tumor 
marker, for example the follicle-stimulating hormone receptor (FSHR) protein, which is 
expressed almost exclusively in tumors. 
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APPENDIX A 
Concentration, purity and quality of RNA isolated from MDA-MB-468, MCF-7, 
Hela, ARPE19, D407 and 293T cancer cell lines. 
 
 
Tabela 2: Concentration and purity of RNA. 
 
 
 
 
 
Cell Line RNA (ng/μL) A260/A280 
MDA-MB-468 1437.3 1.89 
MCF-7 1313.3 1.87 
Hela 679.0 1.79 
ARPE19 620.5 1.83 
D407 1347.1 1.90 
293T 2959.4 1.94 
Figure 27 – Visualization of RNA ribosomal bands (28S, 18S and 5S) to assess the quality of RNA 
isolated from MDA-MB-468, MCF-7, Hela, ARPE19, D407 and 293T cancer cell lines. 
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APPENDIX B 
Detection of α-tubulin in MCF-7 breast cancer cells and DND41 acute 
lymphoblastic leukemia cells by Western blotting. 
 
 
 
 
 
 
Figure 19 – Detection of α–tubulin 
protein in homogenates of MCF-7 
and DND41 cell lines by SDS-PAGE 
and Western Blotting. 
